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8ABSTRACT
Aims
The present study aimed to investigate the effect of amitriptyline in prevention (study III) and
treatment (study II) of chemotherapy-induced peripheral neuropathy (CIPN). The secondary
aims were to evaluate the prevalence and discomfort of CIPN in a clinical cohort
predisposed to neurotoxic chemotherapy agents (study I), grading of neurotoxicity (study IV)
and the changes in intraepidermal nerve fiber (IENF) density during the neurotoxicity
treatment (study V).
Patients
The study included three cancer patient populations treated with neurotoxic chemotherapy at
Helsinki University Hospital, Department of Oncology (studies I-IV) or Gynecology (study III)
and Tampere University Hospital, Department of Oncology (study V). The first study
population was screened between January 2002 and June 2004 from 448 patients aged 20
to 70 years, of whom 152 had neuropathic symptoms and were hence eligible for evaluation
of the burden of neuropathic symptoms (I). Of those 152 symptomatic patients 33 patients
had sensory neuropathic symptoms (numbness, tingling or pain) of at least moderate
severity and were randomised to treatment study (II). Between February 2003 and May 2006
104 patients without previous neuropathy who started neurotoxic chemotherapy  were
randomized to the prevention study (III). Two different neurotoxicity scales were used with
this population (IV). The fifth study consisted of 12 patients aged from 18 to 70 years starting
adjuvant chemotherapy with taxanes or platinum derivatives (V).
Methods
In the first study (I) a questionnaire of chemotherapy adverse effects and neuropathy
symptoms  was used for screening. The intensity of the neuropathic symptoms was
assessed with a Visual Analogue Scale (VAS) (I-III, V). During the clinical visits the patients
were evaluated with physical examination including neurological status (I-III, V). Neuropathy
9was scored according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC)
and Oxaliplatin Scales (II-V), and quality of life (QoL) with the European Organization for
Research and Treatment of Cancer item 30 of the quality of life questionnaire (EORTC QLQ-
C30) for cancer patients (II, III, V). The patients graded neuropathic symptoms by VAS in a
diary twice a week during the whole study period (II-III). The skin biopsies (diameter 3 mm)
were taken from the right distal leg 10 cm above the lateral malleolus at every study visit.
Specimens were fixed in 10% formalin and then embedded in paraffin. Ten-um sections
were immunostained with anti-protein-gene-product 9.5 (PGP 9.5) antibodies. The IENF
count was determined with a light microscope at 400 x magnification blinded to the clinical
status of the patient. Two adjacent skin sections were analyzed to get a proper estimation of
the IENF count. For the estimation of epidermal area the point-counting was performed
using square lattice. The normal value for IENF density was determined to be above 40
fibres per mm2.
Results
Fifty-nine % of the screened patients reported neuropathic symptoms. Tingling (71 %),
numbness (58 %) impaired sensory function (46 %) and pain in hands and feet (40 %) were
the most common symptoms. The median intensity of neuropathic symptoms was 28/100 on
VAS. Neuropathic symptoms were the third most commonly reported adverse effect
symptoms. Every third patient (37 %) with neuropathic symptoms ranked them as the most
troublesome symptom.
Comparing the NCI-CTC sensory and Oxaliplatin Scales the progression of the toxicity from
mild (grade 1 or 2) to moderate or severe (grade 3 or 4) was detected more frequently with
the Oxaliplatin scale. Of the patients with grade 3 or 4 toxicity with Oxaliplatin Scale 23/53
had grade 1 toxicity by the NCI-CTC scale, 18/53 had grade 2 and 12/53 had grade 3
neurotoxicity. The Oxaliplatin Scale was in line with the NCI-CTC scale in 12/53 patients with
grade 3 symptoms.
No significant differences were found between the amitriptyline and placebo groups in the
intensity of the neuropathic symptoms either in the treatment study or in the prevention study
during the follow-up. In the prevention study sensory neuropathy was seen after 3, 6 and 9
chemotherapy cycles in 61 %, 57 % and 76 % of the patients, respectively. Amitriptyline
improved statistically significantly quality of life (QoL) measured with the EORTC QLQ-C30
compared with placebo.
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Reduced IENF density was found in 8/12 patients at baseline. During the follow-up IENF
density increased significantly in six of them and remained unchanged in two. In four patiets
IENF density was normal both at baseline and at the end of follow-up period. Nine patiens
had neuropathic symptoms, but no association was found between neuropathic symptoms
and IENF count.
Conclusion
CIPN is a common, albeit of mild intensity, adverce effect of neurotoxic regimens. There is
no standard global method for assessment of CIPN. No prevention or treatment of CIPN
exists exept limitation of total dose or changing the treatment to a less neurotoxic agent.
IENF density can be markedly reduced in some cancer patients even prior chemotherapy,
which might partly influence  the development of abnormalities in sensation and neuropathic
pain.
INTRODUCTION
The first case report of sensory neuropathy secondary to chemotherapy agent cisplatin was
published over 30 years ago (Kedar et al, 1978). Nowadays, CIPN is a well recognized
adverse event, and the awareness of its significance is increasing as neurotoxic drugs are
used more frequently in adjuvant settings with more patients being cured. Survival benefit of
adjuvant chemotherapy has been demonstrated at least in breast, ovarian, colorectal, lung,
pancreatic and ventricular cancer and sarcomas. In addition, chemotherapy of testicular
cancer and lymphomas is mainly curative. Life expectancy has prolonged also for patients
with advanced cancer due to better treatment options, including multiple chemotherapy
regimens. In advanced cancer, chemotherapy prolongs overall and progression-free survival
and improves QoL, by reducing and preventing cancer-related symptoms.
The most neurotoxic chemotherapeutic agents are vinca-alkaloids, platinum derivatives and
taxanes (Ocean and Vahdat, 2004; Quasthoff and Hartung, 2002). The incidence of
neurotoxicity varies between the different chemotherapy agents. It appears in a dose-
dependent manner and is usually highest when neurotoxic agents are used in combination.
However, the mechanisms of CIPN are not fully understood.
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Incidence of CIPN varies widely depending on cytotoxic agent, treatment schedule (total
dose, dose intensity), combinations of different cytotoxic agents and patient population.
Especially elderly population and patients with a pre-existing disorder of the peripheral
nervous system (e.g. neuropathy associated with diabetes, malnutrition, alcoholism or
inherited neuropathy) are at higher risk of developing severe and irreversible chemotherapy-
induced neuropathy (Ocean and Vahdat, 2004). In the US, 50 % of all malignancies occur in
persons aged 65-95 years. With increasing cancer incidence in the older population, it is
expected that 60 % of all cancers will be detected in elderly patients in the next two decades
(Balducci and Extermann, 2000).
CIPN is an important adverse effect as it may cause dose reductions or discontinuation of
the anticancer treatment, which may deteriorate the prognosis of the patient. In the majority
of the patients CIPN is reversible if recognized early enough and the treatment is
discontinued or the dose is reduced. However, recovery may take months or even years.
Chronic CIPN symptoms reduce significantly physical functioning and QoL of cancer
patients. The typical clinical presentation of peripheral neuropathy is symmetric sensory and
motor impairment in a length-dependent manner (distal extremities first), which causes
paresthesia, numbness, pain and peripheral motor dysfunction.
Interest in CIPN has increased in the last years, including epidemiology, mechanisms,
clinical burden, prevention and treatment of it. A possibility to either prevent or treat CIPN
could thus affect not only physical functioning and QoL of the patients, but it could also
indirectly improve survival.
With this study we aimed at investigating the prevalence and discomfort of neuropathic
symptoms in relation to other toxicities of chemotherapy, and the possible effect of
amitriptyline in prevention and treatment of neuropathic symptoms. In addition, we wanted to
compare two different scales in grading of chemotherapy-induced neurotoxicity and do a
pilot study of the changes of intraepidermal nerve fiber density during neurotoxic
chemotherapy.
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REVIEW OF THE LITERATURE
Anatomy of peripheral nervous system
The peripheral nervous system refers to parts of the nervous system outside the brain and
spinal cord. It includes the cranial nerves and spinal nerves from their origin to their end.
The anterior horn cells motor neurons are located in the gray matter of the spinal cord and
thus are anatomically part of the central nervous system although functionally they belong to
the peripheral nervous system. In contrast to the motor system, the cell bodies of the
afferent sensory fibers lie outside the spinal cord, in dorsal root ganglia.
Nerve fibers outside the spinal cord join to form anterior (ventral) motor roots and posterior
(dorsal) sensory nerve roots (Figure 1). The ventral and dorsal roots combine to form a
spinal nerve. Thirty of the 31 pairs of spinal nerves have dorsal and ventral roots.
Because sensory and motor cell bodies are in different locations, a nerve cell body disorder
typically affects either the sensory or motor component but rarely both. Motor neuron
dysfunction results in muscle weakness or paralysis. Sensory neuron dysfunction results in
abnormal or lost se
Figure 1. A horizontal section
of the spinal cord, and dorsal and
ventral roots and a spinal nerve.
(adopted from
http://www.dartmouth.edu/~humana
natomy/figures/chapter_3/3-2.HTM )
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A peripheral nerve trunk is comprised of axons of multiple neurons bundled in connective
tissue fascicles surrounded by perineurium. The primary afferent axons are classified
according to their diameter and conduction velocity (Table 1, Figure 2).
Table 1. Classification of the primary afferent axons according to their diameter and
conduction velocity (adopted from http://thebrain.mcgill.ca )
Type of nerve
fiber
Information   carried Myelin sheath Diameter
(micrometerers)
Conduction
speed (m/s)
A-alpha proprioception myelinated 13 - 20 80 - 120
A-beta touch myelinated 6 - 12 35 - 90
A-delta pain (mechanical and
thermal)
myelinated 1-5 5-40
C pain (mechanical,
thermal and chemical)
nonmyelinated 0.2 – 1.5 0.5 - 2
Figure 2. Primary afferent axons (adopted from  http://www.cidpusa.org/nerves.htm )
A-alpha fibers are the largest peripheral fibers, functioning as alpha-motoneurons and
proprioceptive sensory fibers. A-beta fibers transfer tactile stimuli, whereas small fibers
(including thinly myelinated A-delta fibers and unmyelinated C fibers) transfer mechanical
pain and thermal stimuli.
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Disorders of the peripheral nervous system
Peripheral neuropathy is a general term that indicates any disorder of the peripheral nervous
system. The term mononeuropathy implies a focal lesion of a single peripheral nerve.
Mononeuropathy multiplex describes the involvement of multiple separate noncontiguous
peripheral nerves either simultaneously or serially. Polyneuropathy refers to simultaneous
malfunction of many nerves throughout the body. Polyneuropathies can be classified in
different ways, such as by cause, hereditary or not, or by part of which the nerve cell is
mainly affected: the myelin sheath (myelinopathy or demyelinating polyneuropathy), the
axon (distal axonopathy), or the cell body (neuronopathy). (England and Asbury, 2004)
Demyelinating polyneuropathy (due to loss of myelin or Schwann cells) affects mainly
heavily myelinated fibers slowing nerve conduction and causing large-fiber sensory
dysfunction (buzzing and tingling sensations), motor weakness and diminished reflexes. It
can be divided to acquired or genetic: acute inflammatory demyelinating (polyradiculitis like
Guillain-Barrè syndrome) and chronic inflammatory demyelinating polyneuropathy or genetic
metabolic disorders (e.g., leukodystrophy). Typical demyelinating polyneuropathy is severe
motor weakness with minimal atrophy. (England and Asbury, 2004; Hughes, 2008)
Axonal polyneuropathy is the most common type of polyneuropathy. It is caused by damage
to the axon transport system for cellular constituents, especially microtubules and
microfilaments, leading to significant axon dysfunction. Axonal polyneuropathies can be
divided according to the type of axon affected: small-fiber, (e.g., Fabry’s disease), large-fiber
or both (England and Asbury, 2004). The smaller fibers at the most distal part of the nerve
are first affected, because they have greater metabolic requirements. Thereafter the axonal
degeneration ascends slowly producing the characteristic distal-to-proximal pattern of
symptoms (stocking-glove sensory loss and weakness). Distal axonopathy is the most
common response of neurones to metabolic or toxic disturbances. The most common
metabolic causes are diabetes, renal failure, and hypothyreosis. A typical example of
nutritional cause is vitamin B12 deficiency. The most common toxic causes for axonal
neuropathy are alcohol and neurotoxic drugs (England and Asbury 2004; Hughes, 2008).
Central hypothesis is that dysfunctional mitochondria in distal axons are a common
mechanism to explain length-dependency of peripheral neuropathies (Lehmann, 2011).
Many polyneuropathies have both motor and sensory involvement and some cause also
dysfunction of the autonomic nervous system. There is some variation in clinical picture of
peripheral neuropathies from different etiologies. Also peripheral neuropathy from a single
etiology may manifest differently in different patients. The most common symptoms of
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peripheral neuropathy are sensory disturbances, including both the negative symptoms of
numbness and sensory loss and the positive symptoms of pain and paresthesias. The
sensory symptoms most often start in the distal extremities in a ‘glove-and-stocking’
distribution. Motor symptoms manifest as distal weakness and muscle atrophy. Deep tendon
reflexes diminish. In addition, autonomic symptoms may occur which can include orthostatic
hypotension or other cardiovascular disturbancies, erectile dysfunction or gastrointestinal
disturbances. (England and Asbury, 2004)
If the cause of polyneuropathy is removed, regeneration is possible, though the prognosis
depends on the duration and severity of the cause. (England and Asbury, 2004; Hughes,
2008)
Neuropathic pain
Neuropathic pain is a consequence of a lesion or disease affecting the somatosensory
system (Jensen et al, 2011). Inflammatory or nociceptive pain is caused by tissue damage or
potentially tissue damaging stimuli, whereas neuropathic pain is produced either by damage
to, or pathological change in the system that normally signals pain. Painful symptoms arising
in an area of altered sensation (hyposensitivity, i.e., impaired sensory function, or
hypersensitivity, i.e., increased sensation to stimuli) refer to neuropathic pain. Neuropathic
pain disorders are divided into central or peripheral neuropathic pain conditions on the basis
of the site of the lesion. Basic characteristics of neuropathic pain are spontaneous pain (pain
arising without stimulus) or abnormal response to non-painful or painful stimuli. Patients may
report dysaesthesias (unpleasant and strange sensations in the skin, such as tingling and
pins and needles), deep seated gnawing pain, abnormal thermal sensations (burning or ice
cold) and less frequently shooting, stabbing, or electric shocks. Features of neuropathic pain
may come out within days of nerve damage or can take months to develop. (England and
Asbury, 2004; Hughes, 2008)
Symptomatic treatment of neuropathic pain is based on modulatory effect of the drug to the
abnormal functioning sensory system. Recent evidence-based guidelines, based on
randomized controlled trials, recommend topical lidocaine in peripheral neuropathic pain with
a limited area of allodynia (e.g., postherpetic neuralgia (PHN), tricyclic antidepressants
(TCAs), gabapentinoids (gabapentin and pregabalin) and serotonin-noradrenalin reuptake
inhibitor (SNRI) drugs (duloxetine and venlafaxine) as the first line choices for neuropathic
pain (Attal et al, 2010, Dworkin et al, 2007). Carbamazepine and oxcarbazepine are drugs
of choice for trigeminal neuralgia. When the first line drugs fail to provide acceptable pain
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relief for NP other than trigeminal neuralgia, tramadol and strong opioids (e.g., morphine or
oxycodone) are recommended, providing the patient has no contraindications for opioid use.
(Attal et al, 2010). The registration trials have used mainly two clinical conditions,  (PHN) and
painful diabetic neuropathy, but other neuropathic pain conditions are far less studied. Some
neuropathic pain conditions, like painful HIV-related neuropathy or painful radiculopathy are
more refractory to treatment than PHN and painful diabetic neuropathy. (Attal et al, 2010).
Recently a new treatment, 8 % capsaicin plaster, has been approved by European
Medicines Agency (EMA) for the treatment of peripheral neuropathic pain in non-diabetic
adults (Astellas, 2011). It is used as a single application every 3 months. Capsaicin is a
highly selective agonist for the transient receptor potential channel Vanilloid-Receptor Type
1 (TRPV1), located in nociceptors. Capsaicin causes initially TRPV1 activation (experienced
as burning pain), and in some days ‘defunctionalisation’ of TRPV1, leading to pain reduction.
It also results in reversible reduction in IENF density. (Anand and Bley, 2011).  Capsaicin
patch has shown efficacy in patients with PHN (Backonja et al, 2008) and painful HIV-related
neuropathy (Simpson et al, 2008).
There is little evidence of the possibilities to prevent neuropathic pain. According to one
small study, risk of PHN can be reduced with low-dose amitriptyline (25 mg) used for 3
months after acute phase (Bowsher, 1997). Prevention of herpes zoster with a vaccine
naturally prevents PHN (Oxman et al, 2005). Risk of postsurgical neuropathic pain can be
reduced by applying surgical techniques that avoid nerve damage (Kehlet et al, 2006).
Optimizing glucose balance and controlling risk factors of atherosclerosis reduce the risk of
painful diabetic neuropathy (Tesfaye et al, 2005). Avoiding predisposition to neurotoxic
agents reduces the risk of painful toxic neuropathy.
Peripheral neuropathies related to malignancies
In a single cancer patient neuropathy with or without pain may be caused by the tumour,
treatment or immunological mechanisms. The most common reason for cancer-associated
neuropathy is infiltration or compression of a nervous structure by the tumour. Main
anticancer treatments, i.e., surgery, radiotherapy and chemotherapy can cause peripheral
nerve damage. Postsurgical neuropathic pain is not an uncommon phenomenon in a cancer
patient, e.g., postmastectomy pain is thought to be consequence of 4-6 % of surgical
procedures for breast cancer (Stevens et al, 1995). The development of radiotherapy
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techniques has decreased the incidence of post-radiotherapy neuropathy, which may be
acute or delayed (presenting after years) (Schierle and Vinograd, 2004).
The Paraneoplastic Neurological Syndrome Euronetwork and the European Federation of
Neurological Societies have summarized the data acquired over the past 8 years on
paraneoplastic syndromes, including those affecting the peripheral nervous system (Koike
et al, 2011). Several types of neuropathies have been reported as paraneoplastic. Subacute
sensory neuronopathy is a classical paraneoplastic neurological syndrome. It occurs mostly
in small cell lung cancer (70–80 % of cases) and sometimes in breast or ovarian cancer,
Hodgkin’s disease or sarcomas. The most usual symptoms are pain and paraesthesiae.
Sensory loss may occur in the face, chest or abdomen, and in deep sensation it leads to
severe sensory ataxia. Neuropathy often precedes the discovery of cancer, and the main
treatment aims at obtaining oncological remission, which remains the best way to stabilize
the neuropathy. (Behin et al, 2008)
Neuropathies related to lymphomas are quite rare and heterogeneous. They are associated
with myelin associated glycoprotein IgM production. Myelin associated glycoprotein is a type
I membrane protein and member of the immunoglobulin superfamily. It is supposed to be
involved in the process of myelination by binding glycoconjugates and mediates certain
myelin-neuron cell-cell interactions. The most aggressive high-grade B-cell lymphomas
usually cause proximal infiltration and no demyelinating polyneuropathy, while Hodgkin’s
lymphoma is associated with no demyelinating polyneuropathy (Behin et al, 2008).
Multiple myeloma itself can cause neuropathy. Therefore, a large proportion of patients who
are started with cancer treatment for multiple myeloma already have neuropathy from their
underlying malignancy or amyloidosis associated to it. For example 81-83 % of bortezomib-
treated multiple myeloma patients had neuropathy before the treatment. Those having
neuropathy prior to neurotoxic chemotherapy develop more severe neuropathy than those
without preceding neuropathy, but the incidence of neuropathy is not increased (Richardson
et al, 2006; Plasmati et al, 2007; Kaley and Deangelis, 2009).
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Chemotherapy induced peripheral neuropathy
Incidence of CIPN varies widely in the literature depending on the study. Approximately 30-
40 % of patients treated with neurotoxic chemotherapeutic agents develop peripheral
neurotoxicity, being highest with cisplatin, paclitaxel, docetaxel, vincristine, oxaliplatin and
bortezomib (Velasco and Bruna, 2010).
Neurotoxic agent, cumulative dose, dose intensity, duration of therapy, and coadministration
of other neurotoxic chemotherapy agents affect to incidence of CIPN (Velasco and Bruna,
2009). In addition, patient related factors such as age, excessive alcohol consumption and
pre-existing co-morbidities predisposing to neuropathy (e.g., diabetes, vitamin B12 deficiency,
or hypothyroidism) increase the risk of CIPN. Patients with previous neuropathy are at risk to
have progression of neuropathy when treated with neurotoxic chemotherapy (Chaudry et al,
2003). This may necessitate the selection of an alternative (less neurotoxic)
chemotherapeutic agent. (Argyriou et al, 2011; Cavaletti, 2009; Kaley and Deangelis, 2009;
Pachman et al, 2011)
Incidence of CIPN in daily practice may be even higher than incidence reported in clinical
trials as patients in trials are highly selected. Especially elderly patients and patients with
comorbidities are underrepresented in the studies. It has also been proposed that CIPN is
underreported by the patients and underrecognised by the doctors (Velasco and Bruna,
2010).
While symptoms recover completely in the majority of the patients, in some cases CIPN is
only partly reversible (Bakitas 2007). Peripheral neuropathy can impair patient’s physical
functioning, activities of daily living (ADL) and QoL (Almadrones et al, 2004; Bakitas, 2007).
Patients who have neuropathy in the upper extremities experience different functional
limitations compared to patients with neuropathy in the lower extremities (Bakitas, 2007).
The former may experience difficulty in tasks demanding fine motoric skills such as buttoning
buttons, zipping zippers, writing or sewing, whereas the latter, especially with advanced
neuropathy can have difficulties in walking, climbing stairs, using car pedals and any activity
which requires good control of balance. Elderly patients may become unable to live
independently because the symptoms can lead to need of assistance in ADL. Depending on
patients´ work, the symptoms may lead to working disability. Patients can be severely
distressed because of functional impairment due to neuropathy.
CIPN can lead to discontinuation or dose reduction of the therapy. Concern has been raised
that dose reduction and early discontinuation of the anticancer therapy might have a
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negative impact on treatment response and survival (Postma et al, 2005). Patients may
choose to endure the distress and limitations caused by CIPN because of fears that their
cancer will progress if their chemotherapy regimen is altered or discontinued (Tofthagen et
al, 2010; Bakitas, 2007).
Symptoms and signs
Depending on the substance used, a pure sensory and painful neuropathy (with cisplatin,
oxaliplatin and carboplatin) or a mixed sensorimotor neuropathy with or without involvement
of the autonomic nervous system (with vincristine, docetaxel and paclitaxel) can ensue
(Pachman et al, 2011; Cavaletti and Marmiroli, 2010; Velasco and Bruna, 2010).
Non-painful sensory symptoms such as numbness, paresthesias and tingling are the most
common initial symptoms. A few patients have neuropathic pain, even at the early course of
treatment. Sensory symptoms start in feet with some chemotherapeutic agents (referring to
length-dependent axonal neuropathy) whereas other agents cause simultaneous
presentation of the symptoms in hands and feet (possibly referring to neuronopathy)
(Bennet, 2010). Some agents (oxaliplatin, paclitaxel) cause both acute transient and chronic
dose-dependent neuropathy, which presumably have different pathophysiological
backgrounds. Motor neuropathy presents as distal motor weakness, and in later phase as
muscle atrophy. Balance difficulties may be caused by damage of large sensory fibers
(causing deteriorated proprioception) and / or distal muscular weakness. (Cavaletti and
Marmiroli, 2010; Velasco and Bruna, 2010)
In sensory testing patients may have hyperesthesia (allodynia, i.e., painful response to non-
painful stimuli, or hyperalgesia, i.e. increased pain sensitivity to painful stimuli) or
hypoesthesia (impaired sensitivity to stimuli) or combination of them depending on the
stimuli (e.g., cold allodynia combined with tactile hypoesthesia). Large sensory fiber loss
results in impaired vibratory and proprioceptive sensation and decreased deep tendon
reflexes. The vibratory perception threshold increases more in feet than in hands in cases of
axonal damage. Small fiber neuropathy leads to abnormal findings in pinprick and thermal
sensation (Swain and Arezzo, 2008; Argyriou et al, 2011).
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Pathogenesis of chemotherapy induced peripheral neuropathy
The peripheral nervous system is targeted commonly by the toxic action of anticancer drugs
and most of these act against the dorsal root ganglia (DRG) neurons or the peripheral nerve
(Cavaletti et al, 2011). Little is known about the mechanisms responsible for the
development of CIPN. The mechanism of neurotoxicity is not necessarily the same as of the
anticancer effect, and multiple mechanisms can contribute to the neurotoxicity. Assumptions
of the pathophysiological mechanisms are based mainly on animal models, and only few
clinical studies have supported various hypotheses suggested by basic research.
Toxicity can affect the axons or the neuronal bodies, generally the dorsal root ganglia of the
primary sensory neurons, described in cisplatin (Krarup-Hansen et al, 2007; Albers et al,
2011) and oxaliplatin (Argyriou et al, 2008b). Cisplatin is an inorganic heavy metal
compound that inhibits deoxyribonucleic acid (DNA) synthesis by forming DNA adducts
(McWhinney et al, 2007). The mechanism of its neurotoxicity is not known. Vinca alkaloids
and taxanes are anti-microtubule agents, which bind with high affinity also to axonal
microtubules.
Current view is that these drugs interfere with mitochondrial energetics, resulting in energy
deficiency that leads to dysfunction of the sodium-potassium pump that maintains the normal
resting potential (Bennett, 2010). As the result, the axons depolarize upnormally to the
threshold necessary for spontaneous discharge The pathophysiological mechanisms
responsible for neuropathic pain are at least partly different depending on the cause of the
nerve damage (Bennett, 2010).
Animal models include inflammation-based models, nerve trauma–induced models, and
chemotherapy-induced models of neuropathic pain. Some scientists have recently identified
abnormalities in mitochondrial structure and function in peripheral sensory fibers that are
associated with neuropathic pain induced by common chemotherapeutic agents.
Interestingly pain can be reversed by agents that enhance mitochondrial function. (Bennet,
2010; Zheng et al, 2011)
High doses of paclitaxel kill sensory fibers as well as motor neurons in rats, but heat
hypersensitivity is very minor or absent (Bennett, 2010). Rats treated with paclitaxel,
vincristine, or oxaliplatin show that both A-fibers and C-fibers have a very high incidence of
abnormal spontaneous discharge (Bennett, 2010). Previous work has proposed that
paclitaxel binds to microtubules making them excessively stable and inhibiting the dynamic
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reorganisation of the microtubule network and cause neuronal death (Bennett, 2010).
However, in the rat models, paclitaxel, vincristine, and oxaliplatin cause neither axonal nor
microtubular abnormality in the saphenous nerve.  All three chemotherapeutic agents cause
partial degeneration of the intraepidermal sensory fibers, and the axonal mitochondria are
abnormally swollen, the cristae have collapsed and the intermembrane space has expanded.
Oxygen consumption in the axons of animals treated with paclitaxel is deficient, with
decreased amounts of ATP produced by both respiratory complex I and complex II.
(Bennett, 2010; Zheng et al, 2011)
Oxaliplatin has been shown to affect voltage-gated sodium-channel kinetics in sensory
neurons, leading to sensory hyperexitability (Binder et al, 2007; Pachman et al, 2011; Park
et al, 2009; Cavaletti and Marmiroli, 2010). Oxaliplatin-induced acute neuropathy is
characterized by cold and mechanical hyperalgesia, leading to hypothesis that sensitization
of the TRPM8 and/or TRPA1 receptors in primary afferent neurons is involved in acute
oxaliplatin-induced pain (Binder et al, 2007; Stengel and Baron, 2009).
Assesment of CIPN
Clinical assessment
The mainstay of assessment of CIPN is clinical evaluation, i.e., history and clinical
examination. The former includes history of symptoms (e.g., paresthesia, numbness, pain),
possible predisposing factors to neuropathy (e.g., diabetes, hypothyreosis, vitamin B12
deficiency and alcohol consumption) and patient’s functional capacity. The latter consists of
testing of various sensory modalities (vibration, touch, joint position sense, pinprick, warm
and cold), muscle strength (especially that of distal muscles, i.e., flexion and extension of
wrists, walking on heel and toe), testing of deep tendon reflexes, Babinski sign, fine motoric
function (e.g., buttoning) and balance (Romberg’s test, walking along line).
Grading of neurotoxicity
There is no standard universally accepted, well-validated assessment tool for CIPN. Several
toxicity grading scales have been developed to score the severity of CIPN. The grading is
based on symptoms and functional capacity reported by the patient and findings in physical
examination. The most commonly used scale is NCI-CTC, that includes separate grading for
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sensory and motor symptoms. Other grading scales used in clinical practice are the WHO
(Miller et al, 1981), Eastern Cooperative Oncology Group (ECOG) (Oken et al, 1982), Ajani
(Ajani et al, 1990) scales and the oxaliplatin grading scale of Levi (Levi et al, 1992; Griffith et
al, 2010; Cavaletti et al, 2010). The oxalipatin grading scale has been developed for
assessing neurotoxicity caused specifically by oxaliplatin as oxaliplatin causes both acute
transient and chronic neuropathy (McWhinney et al, 2009). It differs from the other scales by
focusing not only on the intensity of neuropathic symptoms but also on the duration of the
symptoms. It has been used, so far only for the assessment of CIPN caused by oxaliplatin.
Other but above mentioned neuropathy scores are seldom used in clinical oncology practice.
(Griffith et al, 2010; Cavaletti, 2009; Cavaletti et al, 2011) Patient Neurotoxicity
Questionnaire (PNQ) has been developed for assess the incidence, severity of CIPN, and
experiencing interference with activities of daily living (Shimozuma et al, 2009).
The Total Neuropathy Score (TNS) (Cornblath et al, 1999) is mainly used in clinical research
of neurotoxicity. It is a composite measure that includes both clinical and neurophysiological
components and seems to have a greater sensitivity to CIPN changes than the NCI-CTC
scale (Cavaletti et al, 2010).
Assessment of neuropathic pain
The intensity of pain can be measured by VAS, numerical rating (NRS), or verbal rating
(VRS) scales (Cruccu et al, 2004).  VAS is one of the oldest, easiest and best validated
measures to assess pain (Huskisson, 1974). Among the numerical scales the 11-point Likert
scale (0 = no pain, 10 = worst possible pain) has been most widely used in recent
neuropathic pain studies (Cruccu et al, 2004). Use of NRS or VAS scales is recommended
both in daily practice and clinical trials (Haanpää et al, 2011). The NRS may be easier to use
than the VAS for elderly people and is the most reliable to assess treatment effect in chronic
pain (Dworkin et al, 2005).
The McGill Pain Questionnaire (Melzack, 1975), and the short form of it (Melzack, 1987) are
the most frequently used self-rating instruments for pain measurement and also often used
in treatment trials. They provide data on the various sensory and affective dimensions of
pain but they are not specifically designed to assess neuropathic pain. (Cruccu et al, 2004)
Specific neuropathic assessment scales have been designed to evaluate separately the
various symptoms of neuropathic pain. The Neuropathic Pain Scale (Galer and Jensen,
1997) and Neuropathic Pain Symptom Inventory (Bouhassira et al, 2004) have been
validated specifically for neuropathic pain and are recommended to evaluate treatment
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effects on neuropathic symptoms or their combination especially in clinical trials (Haanpää et
al, 2011).
The Brief Pain Inventory is a patient-completed numeric rating scale that assesses the
severity of pain (Severity scale), its impact on daily functioning (Interference scale), and
other aspects of pain (location of pain, relief from medications) (Cleeland and Ryan, 1994).
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Table 3. Different grading scles of CIPN.
Scale Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
NCIC-CTC
Sensory
neuropathy
None Loss of deep
tendon reflexes or
paresthesia
(including tingling)
but not interfering
with function
Objective sensory
loss or paresthesia,
interfering with
function but not
interfering with ADL
Sensory loss or
paresthesia
interfering with ADL
Permanent sensory
loss that interferes
with function
Motor
neuropathy
None Subjective
weakness but no
objective findings
Objective mild
weakness,
interfering with
function but not
interfering with ADL
Moderate objective
abnormality, severe
functional
abnormality
Paralysis
Ajani
Sensory
neuropathy
None Paresthesia and
decreased deep
tendon reflexes
Mild objective
abnormality,
absence of deep
tendon reflexes, mild
to moderate
functional
b lit
Severe paresthesia,
moderate objective,
severe functional
abnormality
Complete sensory
loss, loss of function
Motor
neuropathy
None Mild transient
muscle weakness
Persistent moderate
weakness, but
ambulatory
Unable to ambulate Complete paralysis
WHO
toxicity
criteria
None Paresthesias
and/or decreased
deep tendon
reflexes
Severe paresthesias
and/or mild
weakness
Intolerable
paresthesias and/or
motor loss
Paralysis
ECOG
None Decreased deep
tendon reflexes,
mild paresthesias,
mild constipation
Absent deep tendon
reflexes, Severe
constipation, mild
weakness
Disabling sensory
loss, severe
peripheral
neuropathic pain,
obstipation, severe
weakness, bladder
dysfunction
Respiratory
dysfunction
secondary to
weakness,
obstipation requiring
surgery, paralysis
confining
Oxaliplatin  grading scale of Levi
None Paresthesia and/or
dysesthesia with
complete
regression within
one week
Paresthesia and/or
dysesthesia with
complete regression
within 14 days
Parenthesis and/or
dysesthesia with
incomplete
regression between
courses
Paresthesia and/or
dysesthesia with
functional
impairment
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Laboratory tests
Electroneuromyography
In the diagnosis of polyneuropathy, electrodiagnostic studies, including nerve conducting
studies and needle electromyography, are judged to be an extension of the neurological
examination (England and Asbury, 2004). The combination of neuropathic symptoms, signs,
and abnormal electrodiagnostic studies provides the most accurate diagnosis of distal
symmetric polyneuropathy (England et al, 2005). Nerve conduction studies are essential for
determining the pathophysiology of peripheral nerves. In nerve conduction studies primary
demyelination is indicated by marked reduction in motor or sensory conduction velocity,
conduction block or increased temporal dispersion, whereas primary axonal loss may be
indicated by a decrease in amplitude of the sensory nerve action potential or the compound
muscle action potential. However, electrophysiological differentiation between demyelination
and axonal loss can be a challenging task as increased temporal dispersion or distal
conduction block due to demyelination may result in amplitude reduction, and in axonal
neuropathy loss of large fast conducting fibers may cause conduction slowing. (Tankisi et al,
2005) In practice, motor nerve conduction velocities below 40 m/s in the upper limb and 30
m/s in the lower limb generally mean demyelination. Lesser degrees of slowing of nerve
conduction velocity indicate peripheral nerve damage, which could be due to axonal loss as
in axonal neuropathy or neuronopathy.  (Hughes, 2008)
Quantitative sensory testing
Electroneuromyography captures only large peripheral fibers. In cases of pure small fiber
neuropathy electroneuromyography remains normal. In these cases quantitative sensory
testing (QST) is indicated to reveal possible abnormal small fiber function.
QST analyses perception in response to external stimuli of controlled intensity. Both large
(touch and vibration) and small fiber function (thermal thresholds) can be evaluated.
Detection and pain thresholds are determined by applying stimuli to the skin in an ascending
and descending order of magnitude. Mechanical sensitivity for tactile stimuli is measured
with plastic filaments that produce graded pressures, such as the von Frey hairs, pinprick
sensation with weighted needles, and vibration sensitivity with an electronic vibrameter.
Thermal perception and thermal pain are measured using a thermode. (Cruccu et al, 2004)
QST has been used for the early diagnosis and follow-up of small-fibre neuropathy and
quantifying mechanical and thermal allodynia and hyperalgesia in painful neuropathic
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syndromes. QST shows both sensory loss (i.e., hypoesthesia and hypoalgesia) and gain
(i.e., hyperalgesia and allodynia) in patients with painful or painless neuropathy. QST
requires standardized stimuli administration, instructions and data evaluation to achieve valid
results. QST may have role in clinical trials, but is rarely used in oncological clinical practice.
(Hlubocky, 2010)
Skin biopsy
Skin biopsy is being increasingly used to evaluate patients with polyneuropathy. There are
different techniques for tissue processing and nerve-fibre assessment, including techniques
for staining, quantification of the intraepidermal and subepidermal nerve fibers, and the use
of different antibodies to distinguish nerve-fibre subtypes (Sommer and Lauria, 2007). The
most common technique involves a 3 mm punch biopsy of skin from the leg. After sectioning
by microtome, the tissue is stained with PGP 9.5 antibodies and examined with
immunohistochemical methods. This staining allows for the identification and counting of
IENF. PGP 9.5 immunohistochemistry has been validated as a reliable method for IENF
density examination with good intra- and interobserver reliability in normal controls and
patients with distal symmetric polyneuropathy. (England et al, 2009) The results are most
commonly expressed as the number of IENF per length of section (IENF/mm). IENF density
declines with age, is lower in males than in females, and is not influenced by weight or
height (Gøransson et al, 2004). The sensitivity of decreased IENF density for the diagnosis
of polyneuropathy is moderate to good (range 45 to 90 %). The specificity of normal IENF
density for the absence of polyneuropathy is very good (range 95 to 97 %). (England et al,
2009). IENF density correlates inversely with both cold and heat detection thresholds. The
European Federation of the Neurological Societies and the Peripheral Nerve Society have
concluded that IENF density is a reliable and efficient technique to confirm the clinical
diagnosis of small fiber neuropathy with a level A recommendation (Joint Task Force, 2010).
A Finnish group has published a method of analysis of IENF (Koskinen et al, 2005).
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Neurotoxic agents
The most neurotoxic chemotherapeutic agents are vinca alkaloids, cisplatin and its
derivatives, and taxanes (Quastohoff and Hartung, 2002; Ocean and Vahdat, 2004). There
are also other neurotoxic drugs like thalidomide and bortezomib for myeloma and
ixabepilone for breast cancer (Mohty et al, 2010; Cavaletti and Marmiroli 2010). Depending
on the agent, CIPN can be pure sensory and painful neuropathy (with cisplatin, carboplatin)
or mixed sensorimotor neuropathy with or without involvement of the autonomic nervous
system (with vincristine, taxanes, and other drugs). Both cisplatin and ifosfamide can cause
acute or delayed central nervous system toxicity (Sioka and Kyritsis, 2009).
The incidence and severity of neuropathy depend on the agents, absolute dose, cumulative
dose, treatment schedule, duration of infusion, and presence of concomitant medications
and comorbidities (Swain and Arezzo, 2008; Carlson and Ocean, 2011).
Table 2 summarizes typical symptoms and signs of CIPN caused by different neurotoxic
chemotherapeutic agents.
Table 2. Typical symptoms and signs for chronic CIPN (modified from Cavaletti et al, 2011).
Drug Touch, thermal,
pain sensation
impairment
Vibration, position
sensation
impairment, ataxia
Neuropathic
pain
Motor
impairme
nt
Autonomic
symptoms
Cisplatin ++ +++ ++ - +
Carboplatin + ++ - - -/+
Oxaliplatin ++ +++ + - -/+
Paclitaxel ++ ++ + ++ -/+
Docetaxel ++ + + + -/+
Vincristine ++ + ++ ++ +++
Bortezomib +++ + +++ + -/+
Thalidomide ++ + + + -
-, absent; -/+, uncertain; +, rare; ++, common; +++, very frequent
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Microtubule targeting agents
Tubulin, a member of a small family of globular proteins, is one of the most established and
clinically validated targets in oncology. Microtubules are polymeric filaments composing of -
tubulin and -tubulin monodimers that mediate intracellular transport, signalling, and mitosis
(Carlson and Ocean, 2011). They have a key role in a range of cellular functions, including
cell division and growth (Swain and Arezzo, 2008). Among other things microtubules are a
major component of the mitotic spindle that separates chromosomes during eukaryotic cell
division. (Lee and Swain, 2006; Swain and Arezzo, 2008)
The anti-mitotic compounds are classified into two main groups: microtubule-stabilizing
agents (such as the taxanes and the epothilones) and microtubule-destabilizing agents
(such as the vinca alkaloids) (Swain and Arezzo, 2008). Microtubule-stabilizing agents block
mitosis, and induce cell death (Lee and Swain, 2006). Whereas vinca alkaloids inhibit
incorporation of tubulin into microtubules (Perez, 2009; Carlson and Ocean, 2011), the
taxanes appear to inhibit microtubule disassembly by inhibiting dynamic reorganization of
the microtubule network (Lee and Swain, 2006; Swain and Arezzo, 2008). Microtubule-
stabilizing agents also bind with high affinity to axonal microtubules causing neurotoxicity
(Swain and Arezzo, 2008; Lee and Swain, 2006). The affinity for tubulin differs among
compounds and is supposed to be a reason for the distinct neurotoxic profile of these drugs.
Axonal swelling in both myelinated and unmyelinated fibers leads to loss and alteration of
length and arrangement of axonal microtubules (Argyriou et al, 2011; Lee and Swain, 2006;
Swain and Arezzo, 2008; Carlson and Ocean, 2011).
Severe peripheral sensory neuropathy (grade 3 or 4) develops in as many as 30 % of
patients treated with microtubule targeting agents (Lee and Swain, 2006). Typical clinical
presentations are summarized in Table 2.
Taxanes
Taxane-based cytotoxic chemotherapies are among the most potent agents for the
treatment of a variety of types of cancers including breast, lung, head and neck, gastric,
prostate and ovarian cancers and are standard components of many therapeutic regimens,
too (Argyriou et al, 2011; Galaal et al, 2011; Perez, 2009).
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Taxanes produce frequent dose-dependent, symmetric, axonal mixed, predominantly
sensory distal neuropathy. Approximately 60–90 % of the patients receiving taxanes develop
mild or moderate neuropathy. Severe peripheral neuropathy (grade 3 or 4) occurs in 30 % of
patients, but it is usually reversible resolving gradually after cessation of the treatment. (Lee
and Swain, 2006; Argyriou et al, 2008a; Argyriou et al, 2011) Paclitaxel is more neurotoxic
than docetaxel (Argyriou et al, 2011; Lee and Swain, 2006).
Docetaxel
Docetaxel is a semisynthetic taxoid, extracted from the European yew tree (Argyriou et al,
2008a). Common dose is 75-100 mg/m2 every three weeks (q3w), 50 mg/m2 biweekly and in
combination treatment (carboplatin, cisplatin, cyclophosphamide, doxorubicin, capecitabine,
5-fluorouracil) usually 75mg/m2. (Baker et al, 2009; Argyriou et al, 2011)
Neuropathic symptoms are usually paresthesias (skin sensation such as burning, prickling,
itching or tingling), numbness, sensory loss, weakness in hands and feet. Many patients
have clumsiness, loss of dexterity and unsteadiness of gait, which causes disability. (Baker
et al, 2009)
In monotherapy CIPN is usually mild and predominantly sensory (Lee and Swain, 2006;
Swain and Arezzo, 2008). The mean cumulative dose to onset of grade 1 or 2 neuropathy is
over 371 mg/m2 (Lee and Swain, 2006; Carlson and Ocean, 2011). Docetaxel at dose 100
mg/m2 leads to grade 3 or 4 sensory neuropathy in 0-17 % of patients (Swain and Arezzo,
2008; Carlson and Ocean, 2011) and to motor neuropathy in 0-9 % (Lee and Swain, 2006),
and at dose 75 mg/m2 sensory neuropathy grade 3 or 4 occurs in 2-4 %. (Lee and Swain,
2006; Carlson and Ocean, 2011; Argyriou et al, 2008a; Argyriou et al,  2011, Vasey et al,
2004)
In adjuvant treatment with a combination of doxorubicin and docetaxel sensory neuropathy
was reported in over 10 % of patients (grade 3: 0.4 %) and grade 1 motor neuropathy in less
than 10 % (grade 3 to 4: 0.4 %). When using a combination of  docetaxel, doxorubicin, and
cyclophosphamide sensory neuropathy was reported in over 10 % (grade 3 to 4: 0 %) and
motor neuropathy in less than 10 % (grade 3 to 4: 0 %). In two trials of metastatic disease
treatment (docetaxel-cisplatin-5-fluorouracil) sensory neuropathy was reported in over 10 %
(grade 3 to 4: 9 %) and motor neuropathy in less than 10 % (grade 3 to 4:1.3 %). When
docetaxel was used in combination with prednisone sensory neuropathy was found in over
10 % (grade 3 to 4: 1 %) and motor neuropathy in less than 10 % (grade 3 to 4: 0%). It is
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unproven whether corticosteroids reduce the incidence of neuropathy or not. (Baker et al;
2009).
Paclitaxel
Paclitaxel was originally derived from the bark of the western yew tree, Taxus brevifolia
(Argyriou et al, 2008a; Ocean and Vahdat, 2004). The common dose is 175-250mg/m2 (q3w)
and 80-100mg/m2 (weekly) (Swain and Arezzo, 2008). Infusion time can be 1, 3 or 24 hours
(Lee and Swain, 2006).
Acute tingling in fingertips and toes may occur within 24 hours after paclitaxel infusion (Lee
and Swain, 2006). Sensory neuropathy presents as paresthesia, numbness and burning
pain appearing first in the toes and then in the fingers (Lee and Swain, 2006; Swain and
Arezzo, 2008). Paresthesiae occur in distal lower extremities with a glove-and-stocking
distribution and is most severe on plantar surfaces (Lee and Swain, 2006). Motor neuropathy
is usually mild and presents as muscle weakness when climbing stairs. Fine motor skills may
be worsened. (Argyriou et al, 2008a)
Common non-neuropathic paroxysmal pain reaction seems to involve mainly muscles
(myalgia) and bones of lower extremities. It usually occurs 2 to 4 days after paclitaxel
infusion and resolves typically within 5 to 6 days. Myalgia is generally mild and occurs rarely
at doses below 170 mg/m2. Patients receiving doses from 200 to 250 mg/m2 may face
myalgia more often, which tend to be mild to moderate in severity. (Carlson and Ocean
2011)
Severe neuropathy usually occurs at cumulative doses of 1,000-1,400 mg/m2 (Carlson and
Ocean, 2011). Neuropathy is less common with weekly regimen or lower doses per cycle
(Mauri et al, 2010; Carlson and Ocean, 2011; Argyriou et al, 2011). Severe peripheral
neuropathy (WHO grade 3 or 4) was reported in 7 % at dose 175 mg/m2 but only in 3 % at
dose 135 mg/m2 (Lee and Swain, 2008). In another trial, grade 3 or 4 sensory peripheral
neuropathy was observed in 33 % at dose 250 mg/m2, in 19 % at 210 mg/m2, and in 7 % at
175 mg/m2 (Carlson and Ocean, 2011; Lee and Swain, 2008). In addition, infusion time
influences neurotoxicity: severe (grade 3 or 4) neuropathy occured in 13 % with 3 hours
infusion time and in 7 % with 24 hours infusion (Argyriou et al, 2008a; Carlson and Ocean,
2011; Lee and Swain, 2008).
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A randomized combination trial comparing docetaxel-carboplatin to paclitaxel-carboplatin for
ovarian or peritoneal cancer showed that the former treatment was significantly less
neurotoxic: grade 3 or 4 sensory neurotoxicity in 11 % versus 30 % and grade 3 or 4 motor
neurotoxicity in 3 % versus 7 % (Vasey et al, 2004).
Avoiding paclitaxel cumulative doses greater than 200-250 mg/m2 and giving taxanes as a
continuous infusion over 24 hours may possibly decrease the incidence of CIPN (Nahleh et
al, 2010).
Nab-Paclitaxel
Nab-Paclitaxel is an albumin-bound 130-nm particle form of paclitaxel for breast cancer. The
drug was developed to avoid the hypersensitivity reactions and peripheral neuropathy
associated with the surfactant vehicles necessary in paclitaxel formulations. (Gradishar et al,
2005;Carlson and Ocean, 2011)
A randomized trial comparing nab-paclitaxel 260 mg/m2 used with every three week
treatment schedule (q3w) with standard paclitaxel 175 mg/m2 showed that grade 3 sensory
neuropathy was significantly more common in the nab-taxel group than in the paclitaxel
group (10 % vs 2  %). However, it improved radiply (median 22 days). (Gradishar et al,
2005)
In a randomized study comparing nab-paclitaxel 300 mg/m2 q3w, 100 mg/m2 weekly, or 150
mg/m2 weekly or docetaxel 100 mg/m2 q3w the incidence of sensory neuropathy was more
common in patients who received nab-paclitaxel q3w and 150 mg/m2 weekly regimens. The
incidence of sensory neuropathy was similar in patients who received nab-paclitaxel or
docetaxel, but recovery from sensory neuropathy occured more rapidly after nab-paclitaxel
compared with docetaxel. Median time to improvement in grade 3 sensory neuropathy (to
grade 2 or less) was 22, 22 and 19 days for nab-paclitaxel 300 mg/m2 q3w, 100 mg/m2
weekly, and 150 mg/m2 weekly, respectively, compared with 37 days for patients who
received docetaxel 100 mg/m2 q3w. (Gradishar et al, 2011)
Cabazitaxel
Cabazitaxel is a new semisynthetic taxane derivative. It is partially synthesized as a single
diastereoisomer from 10-deacetylbaccatin III, the major natural taxoid derived from the
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needles of various Taxus species. Hydroxyl groups present in docetaxel are replaced with
methoxy groups in cabazitaxel. (Sartor et al, 2010; de Bono et al, 2010)
Cabazitaxel has antitumor activity in a variety of docetaxel-refractory in vitro and in vivo
models. It is clinically active in women with taxane resistant metastatic breast cancer and in
men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
The recommended cabazitaxel dose is 25 mg/m2 intravenously over 1 hour on 21-day cycle
in combination with oral prednisone 10mg/day. (Sartor et al, 2010)
In the randomized phase 3 TROPIC trial cabazitaxel was compared to mitoxantrone and
prednisone treatment in metastatic castration-resistant prostate cancer that had progressed
during docetaxel-chemotherapy. Patients with grade 2 or higher peripheral neuropathy in
association with previous docetaxel treatment were excluded from the study (de Bono et al,
2010). Peripheral neuropathy (all grades) was reported during the study in 14 % patients in
the cabazitaxel group and in 3 % in the mitoxantrone group. Grade 3 to 4 neuropathy was
reported by 1 % in both groups. Cumulative neurotoxicity was not reported. (Sartor et al,
2010; de Bono et al, 2010; Pal et al, 2010; Oudard, 2011)
Vinca-alcaloids
Vinca alcaloids include both natural alkaloids, such as vincristine and vinblastine, and semi-
synthetic compounds, such as vinorelbine and vinflunine. These are used for the treatment
of acute leukemia, lymphomas, Kaposi’s sarcoma, breast, ovarian, testicular, brain and lung
cancer. The affinity for tubulin differs among vinca alkaloid compounds and this biochemical
property is supposed to explain the distinct neurotoxic profile of these drugs. (Argyriou et al,
2011; Cavaletti and Marmoroli, 2010)
Vincristine, a first-generation and the most toxic vinca alkaloid, is mainly used in non-
Hodgkin's and Hodgkin`s lymphoma as a part of combination chemotherapy, in treatment for
leukemia, Wilm’s tumor, and sometimes as an immunosuppressant in treating thrombotic
thrombocytopenic purpura or idiopathic thrombocytopenic purpura (Argyriou et al, 2011). It is
supposed that vincristine causes structural changes in the microtubules by binding to tubulin
and disrupting axonal transport causing primary axonal degeneration (Lee and Swain, 2006;
Swain and Arezzo, 2008; Argyriou et al, 2011).
Usual vincristine dose is 1.4 mg/m2 per single dose with an upper limit of 2 mg for single
doses. The earliest symptoms of neuropathy develop after 5-6 mg, but considerable toxicity
is commonly not seen below the cumulative dose of 15-20 mg (Argyriou et al, 2011). Mixed
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sensory/motor polyneuropathy is the most common and usually dose-limiting side effect of
vincristin (Sioka and Kyritsis, 2009). Nearly all patients develop some degree of neuropathy
during the treatment and the neuropathy is still progressing (“coasting”) in every third
patients after discontinuation of the treatment (Swain and Arezzo, 2008; Carlson and Ocean,
2011). Symptoms of autonomic neuropathy include mild-to-moderate constipation; cases of
paralytic ileus and megacolon have also been documented (Swain and Arezzo, 2008;
Carlson and Ocean, 2011). Hepatic insufficiency is a risk factor for more severe neuropathy
(Argyriou et al, 2011).
Vinorelbine is a semi-synthetic third generation vinca alkaloid inhibiting tubulin
polymerisation and microtubule assembly (Aapro and Finek, 2011). It has exhibited efficacy
in lung, breast, bladder, ovarian and testicular cancer (Velasco and Bruna, 2009). Common
intravenous dose both in single and combination therapy is 25-30 mg/m2 and administration
schedule depends on the combination agent (Velasco and Bruna, 2009). Oral vinorelbine is
commonly administered at the dose of 60 mg/m2 once a week and at the dose of 60-80
mg/m2 when used in combination on days 1 and 8 every 3 weeks (Aapro and Finek, 2011).
The vinorelbine and vinflunine-induced neuropathy is primarily sensory, usually mild to
moderate in severity, cumulative, generally reversible after discontinuation and milder than
the vincristine-caused neuropathy (Swain and Arezzo, 2008). The incidence of vinorelbine-
induced neuropathy varies from 6 to 29 %, and grade 3 to 4 sensory neuropathy occurs in 0-
6 % of patients. In the study oral vinorelbine in combination with capecitabine caused grade
3 to 4 neurotoxicity in 1 % (Swain and Arezzo, 2008; Velasco and Bruna, 2009; Carlson and
Ocean, 2011; Aapro and Finek, 2011).
Vinflunine, a novel vinca alkaloid derivative for advanced breast cancer is a close analog of
vinorelbine and exhibits antivascular, antiangiogenic, and antimetastatic activity (Swain and
Arezzo, 2008; Argyriou et al, 2011). At common dose (320 mg/m2 every 3 weeks) it seems
to be even less neurotoxic than vinorelbine: in a phase II study grade 1 to 2 sensory
neuropathy was reported in 13 % of the patients and no grade 3 neuropathy was seen; 3 %
of the patients had grade 3 ileus (Campone et al, 2006).
Vinblastine is mostly used for Hodgkin’s desease at dose 6 mg/m2 on days 1 and 8 every 28
days. Neuropathy is usually mild and occurs in 8 % (Argyriou et al, 2011).
Epothilones
Epothilones, a novel class of microtubule-stabilizing agents, was identified in the early
1990’ies. This class includes the natural epothilones—epothilone B (EPO906, patupilone)
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and epothilone D (KOS-862) and the semisynthetic epothilone analogs ixabepilone and ZK-
EPO. The epothilones are produced by the myxobacterium Sorangium cellulosum. They
have potent in vitro anticancer activity, including in taxane-resistant cell lines. Their in vivo
activity is, however, only moderate at most, and they have a poor metabolic stability and
unfavourable pharmacokinetics. In contrast to most taxanes they have lower susceptibility to
tumor resistance. Epothilones have shown prolonged remissions and improved survival in
various types of refractory, treatment-resistant malignancies. (Swain and Arezzo, 2008;
Argyriou et al, 2011; Carlson and Ocean, 2011)
Epothilones differ from other microtubule inhibitors in their precise binding sites and/or
affinities for tubulin isoforms (Swain and Arezzo, 2008; Carlson and Ocean, 2011). Damage
to the ganglion soma cells and peripheral axons through disruption of microtubules of the
mitotic spindle and by interference with the axonal transport in the affected neurons may
significantly contribute to the pathogenesis of epothilones-induced peripheral neuropathy. An
interference with the physiological microtubule function may influence on the clinical
manifestation of peripheral neuropathy, as intact microtubules are required for both
anterograde and retrograde axonal transport. (Swain and Arezzo, 2008)
The primary dose-limiting toxicity of epothilones is severe diarrhea. Similar to taxanes,
however, peripheral neuropathy was described as a significant nonhematological toxicity of
epothilones in phase II clinical studies. Epothilones primarily produce axonal, dose-
dependent, sensory distal peripheral neuropathy, which is reversible in most cases after
discontinuation of the treatment. (Argyriou et al, 2011)
Epothilone-induced neuropathic symptoms and signs are commonly similar to those caused
by taxanes. In studies the incidence of severe (grade 3 to 4) sensory neuropathy varies from
6 to 21 %, while neuropathy of any grade has been reported in up to 71 % of the exposed
patients (Argyriou et al, 2011).
Ixabepilone
Ixabepilone was approved by the United States Food and Drug Administration (FDA) for the
treatment of anthracycline- and taxane-pretreated or refractory metastatic breast cancer in
2007 (Fornier, 2007). In phase II and III trials of ixabepilone (40 mg/m2 intravenously every 3
weeks) neuropathy was primarily sensory ranging from 20 % (grade 3: 1 %) in untreated
early breast cancer to 67 % (grade 3: 12-20 %) in antracycline and taxane-resistant
metastatic breast cancer. Neuropathy was leading to a dose reduction in 72 % of the
patients (constant grade 2 or temporary grade 3 symptoms) and to permanent
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discontinuation of the therapy in 21 % of the patients. After a dose reduction the symtoms
improved to the baseline level or to grade 1 or did not progress in 80 % of the patients. The
recovery took place in 6 weeks, and 70 % of the patients had a total resolution within
approximately 8 weeks (Fornier, 2007; Argyriou et al, 2011). A lower dose per cycle (6
mg/m2/day on days 1–5 3-weekly) might cause a lower incidence and severity of peripheral
sensory neuropathy; grade 1 to 2: 52-54 %, grade 3: 2 % (Fornier, 2007; Argyriou et al,
2011). However, the EMA refused a marketing authorisation for ixabepilone in 2008 as the
benefits of the drug in the treatment of breast cancer did not outweigh its risks. The
Committee was particularly concerned over neuropathy (Argyriou et al, 2011; Fornier, 2007).
It seems that second generation epothilones do not provide any improved safety in
neurotoxicity compared with other microtubule-stabilizing agents (both older and newer)
(Argyriou et al, 2011).
Eribulin
Eribulin mesylate is a non-taxane synthetic macrocyclic ketone analogue of halichondrin B.
Although eribulin is characterized in the group of antitubulin drugs, its tubulin interactions
appear to be unique: by inhibiting mitotic spindle formation, eribulin causes irreversible
mitotic block, which ultimately leads to cell cycle arrest in the G2-M phase and apoptosis
(Cortes, 2011). Eribulin (1.4 mg/m2 intravenously q3w on day 1 and 8) is indicated in the
treatment of taxane and antracycline pretreated metastatic breast cancer. In all three
metastatic breast cancer phase II studies eribulin has been reported to have a low incidence
of peripheral neuropathy overall, and severe peripheral neuropathy was limited to grade 3
only. (Cortes, 2011)
Platinum derivatives
Cisplatin, carboplatin, and oxaliplatin are the platinum derivatives for the treatment of
colorectal, ovarian, breast, head and neck, lung, and bladder cancers, as well as
lymphomas, sarcomas and germ cell tumors. Cisplatin was the first platinum derivative
approved for use in anticancer therapy in 1978. Carboplatin was approved in 1989 and the
third generation oxaliplatin in 2002. Cisplatin, carboplatin, and oxaliplatin differ in their
solubility, chemical reactivity, oxygenated leaving groups, pharmacokinetics, and toxicity
.(McWinney et al, 2009)
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Platinum derivatives inhibit DNA synthesis by forming DNA adducts (McWinney et al, 2009).
Primary site of neuropathy is assumed to be the involvement of large DRG cell bodies
(neuronopathy) and the secondary degeneration of large, long myelinated fibers both in the
limbs and in the spinal cord. Cisplatin affects axonal degeneration, but demyelination has
also been reported. (Schlippe et al, 2001; Argyriou et al, 2011) Oxaliplatin affects mostly
through DNA damage (Alcindor and Beauger, 2011).
The first symptoms of platinum-induced neuropathy are numbness, tingling or painful
paresthesias in the hands and/or feet in a stocking-glove distribution appearing one month
after initiating the treatment. In addition, patients develop subacute distal dysesthesias,
areflexia, sensory ataxia and loss of proprioception and vibratory sensation. Loss of motor
function has been reported in patients treated with cisplatin. DRG cell degeneration and
spinal cord dorsal columns damage can cause Lhermitte's phenomenon (an electric shock-
like sensation on bending the neck) (Argyriou et al, 2011; Pasetto et al, 2006). After
discontinuation of cisplatin or oxaliplatin treatment, the symptoms may still progress for up to
two months (‘coasting’) (von Schlippe et al, 2001; Albers e et  al t al, 2011). Thereafter
neuropathy is gradually recovering, but in case of a severe neuropathy the recovery may be
incomplete (Argyriou et al, 2011; Pasetto et al, 2006).
Symptoms and signs are symmetric and generally more severe distally. In neurological
examination reduced vibration and joint position sensations (evidence of large fibre sensory
loss) and diminished or absent muscle stretch reflexes can be found. Decreased pinprick
sensation is a consequence of diminished small fibre sensation. Severe proprioceptive loss
may present as sensory ataxia leading to functional disability. (von Schlippe et al, 2001;
Albers et al, 2011; Swain and Arezzo, 2008)
In nerve conduction studies done in patients receiving oxaliplatin, neurophysiological
features of neuropathy became evident despite the lessening of symptoms. Because of this
it is suggested that a reduction in ‘positive’ symptoms (such as pain and paraesthesiae)
might be related to large fibre loss, which may occur concurrent with the development of
‘negative’ features such as numbness (Kiernan, 2007). Abnormalities in sodium channels,
mitochondrial dysfunction and DRG cell atrophy due to accumulation of platinum compounds
are suggested to explain axonal degeneration (Cavaletti and Marmiroli, 2010, Argyriou et al,
2011). The typical clinical features of platinum derivatives are summarized in Table 2.
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Cisplatin
Cisplatin is the first heavy metal used as an antineoplastic agent since the early 1970’ies to
treat lung, ovarian, testicular, bladder, head and neck, endometrial and breast cancer.
Dosage used in clinical practice varies between 50 to 100 mg/m2 given intravenously every
three to four weeks and 20 mg/m2 daily for 5 days or weekly. (Albers et al, 2011)
The incidence and severity of neurotoxicity are mainly determined by the cumulative cisplatin
dose. The incidence of neuropathy varies between 30 % and 100 % (median 57 %). With
cumulative dose 300–400 mg/m2 up to 64 % of the patients have grade 3 to 4 peripheral
neuropathy (Velasco and Bruna; 2009, Argyriou et al, 2011; Albers et al, 2011). Generally
the symptoms appear in 85 % of the patients at cumulative doses 300-600 mg/m2. (von
Schlippe et al, 2001; Albers et al, 2011; Argyriou et al, 2011)
The symptoms of cisplatin-induced neuropathy appear as numbness, tingling or painful
paresthesias in one month, progrediating during and even after the treatment (‘coasting’) to
areflexia and sensory ataxia. Lhermitte’s symptom and/or muscle cramps have been
described. Motor symptoms may occur with high doses. Recovery is slow, and cisplatin-
induced neuropathy is irreversible in approximately 30–50 % of patients. (Albers et al, 2011;
Argyriou et al, 2011)
Oxaliplatin
Oxaliplatin is widely used in treatment of colorectal cancer. It has also been studied in other
gastrointestinal malignancies like gastroesophageal and pancreatic cancers. Currently
recommended doses for oxaliplatin are 85 mg/m2 daily every 2 weeks, 130 mg/m2 daily as a
2–6 hour infusion every 3 weeks or 175 mg/m2 daily as a chronomodulated infusion every 3
weeks. (Pasetto et al, 2006)
Oxaliplatin produces both a reversible acute and partly irreversible cumulative neuropathy,
which are two distinct clinical syndromes. The acute neuropathy is characterized by cold-
related and transient sensory paresthesia and dysesthesia in mouth, throat, perioral region,
and upper limbs, and by motor cramps and/or muscle spasms in throat muscles. The dose-
limiting cumulative peripheral sensory neuropathy has the typical features of platinum drug-
induced peripheral neuropathy. (Velasco and Bruna, 2010; Pasetto et al, 2006)
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Acute symptoms are very common, experienced by 60-90 % of the patients. The acute
neuropathy occurs during or after the infusion within the next few days. The muscular
symptoms are triggered or enhanced by exposure to cold. A smaller number of patients
experience slurred speech, jaw pain during chewing, paresthesias in the limbs or calf
cramps when walking. These symptoms can last for days to weeks. One of the most fearful
symptoms is pharyngo-laryngo-dysesthesia accompanied by a sensation of shortness of
breath without any objective evidence of respiratory distress. Usually it is transient lasting
from a few seconds to a few hours. It may be cold-triggered and may increase in both
duration and severity with repeated administration. Acute neuropathy is always reversible
(Velasco and Bruna, 2010; Pasetto et al, 2006). The acute neurotoxicity is explained as a
functional chanellopathy of axonal sodium channels (Park et al, 2009).
Oxaliplatin induces also cumulative distal neurotoxicity, which can be irreversible. The dose-
limiting, cumulative sensory neurotoxicity is seen in 10–15 % of patients after cumulative
doses of 780–850 mg/m2 (de Gramont et al, 2000), however, 74 % of patients recovered
from grade 3 neurotoxicity. The median recovery time is 13 weeks, but symptoms can
persist even for 2 years or more in up to 10 % of the patients. The risk of permanent
neuropathy is significantly increasing at cumulative dose over 1,000 mg/m2. Cumulative
neurotoxicity causes dose reductions or discontinuation of the therapy relatively often (in 20
% of the patients after 6 cycles, in 38 % after 9 and in 63 % after 12 cycles). (Kiernan, 2007;
Mitchell et al, 2006; Velasco and Bruna, 2010; Pasetto et al, 2006)
The treatment schedule has also influence on the risk for peripheral neuropathy. Based on
indirect comparisons, oxaliplatin with weekly bolus of 5-fluorouracil and leucovorin (FLOX)
seemed to cause less grade 3 neuropathy (8 %) than with continuous 5-fluorouracil and
leucovorin (FOLFOX) (12 %), but there is no direct comparison study. A randomized trial of
FOLFOX 4 versus scheduled intermittent oxaliplatin (OPTIMOX 1) was associated with a
slight reduction in grade 3 neuropathy (18 % versus 13 %). The combination of oxaliplatin
(130 mg/m2) either with capecitabine (XELOX) or with infusional 5-fluorouracil regimen
(FOLFOX4) caused equally neuropathy (grade 3 or 4 neurotoxicity 17 %). (Pasetto et al,
2006; Alcindor and Beauger, 2011)
Carboplatin
Carboplatin is used as a treatment for ovarian and lung cancer. It is typically used in
combination with another chemotherapeutic agents like taxanes, vinorelbine, etoposide or
gemcitabine. As compared to other platinum derivatives, neurotoxicity is less frequent (4 to 6
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%) and relatively mild. The risk of neurotoxicity is more dependent on the partnering agent.
Risk of carboplatin-induced peripheral neurotoxicity increased in patients older than 65 years
and in patients previously treated with cisplatin. (McWhinney et al, 2009)
Bortezomib, thalidomide and lenalidomide
Bortezomib, thalidomide and lenalidomide are used in treatment of multiple myeloma.
Bortezomib is a proteasome inhibitor, whereas thalidomide and lenalidomide suppress the
synthesis of tumor necrosis factor alfa (TNF-) (Mohty et al, 2010).
Bortezomib
Bortezomib is the first proteasome inhibitor to be investigated in humans. Bortezomib-
induced peripheral neuropathy appears to be a proteasome-inhibitor class effect. At the
molecular level, mitochondrial and endoplasmic reticulum damage seems to play a key role
in bortezomib-induced peripheral neuropathy, since bortezomib is able to activate the
mitochondrial-based apoptotic pathway (Mohty et al, 2010; Pei et al, 2004). Some
autoimmune or inflammatory factors can be triggers for the apoptotic process. (Richardson
et al, 2006; Mohty et al, 2010)
Bortezomib-induced neuropathy is length-dependent, sensory, axonal polyneuropathy and
affects especially small fibers. The symptoms are pain, paresthesia, burning sensation,
dysesthesia, numbness and sensory loss, affecting feet more than hands in a stocking-and-
glove distribution. Changes in proprioception can also occur. Motor impairment is rare (less
than 10 %). Orthostatic hypotension has been reported in 10 % of the patients (grade 3: 4
%). (Mohty et al, 2010)
Bortezomib-induced neuropathy typically occurs within the first treatment cycles and does
not increase significantly thereafter. Overall incidence of peripheral neuropathy is up to 40 %
(30 % grade 1 to 2: 30 %, grade 3 to 4: less than 10 %). However, some patients develop
severe symptoms immediately after starting bortezomib. The symptoms do not disappear
between the treatment cycles. (Richardson et al, 2006; Mohty et al, 2010)
The neurotoxicity depends on the route of administration (neurotoxicity in 38 % of the
patients with subcutaneous vs. 53 % with intravenous administration) (Moureau et al, 2011),
treatment schedule (intervals between the cycles, low-dose weekly vs. three-weekly
schedule), dose per cycle (1 mg/m2 vs  1.3  mg/m2) and total dose (Mohty et al, 2010;
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Richardson et al, 2006). The concomitant use of other agents, in particular the addition of
thalidomide, seems surprisingly not to affect the risk of bortezomid-induced peripheral
neuropathy. It is possible that thalidomide has a protective effect with respect to bortezomib
through its anti-inflammatory action that inhibits TNF- . Bortezomib-induced peripheral
neuropathy seems to recover after discontinuation or reduction of doses within some months
(Mohty et al, 2010).
Thalidomide
In the late 1950’ies thalidomide was used as a sedative–hypnotic agent, but because of its
teratogenic effects it was withdrawn in 1961. Later, the therapeutic use of talidomide has
been reintroduced in the treatment of many dermatologic, gastrointestinal, rheumatologic,
and oncologic conditions. (Plasmati et al, 2007) Common single dose is 200 mg a day
(Ghosh and Ghosh, 2010).
The mechanisms of thalidomide-induced peripheral neuropathy are not clear. Thalidomide
causes reduction in nerve blood supply due to the anti-angiogeneic properties. Variations in
genes involved in drug’s neurotoxicity are likely to have an impact on whether an individual
patient will develop this adverse effect (Cavaletti and Marmiroli, 2010; Mohty et al, 2010).
Thalidomide causes mostly mixed sensory-motor axonal neuropathy. It affects mainly small
sensory fibers, but also in some extent large fibers. Motor impairment is rare but possible in
the most severe cases. The clinical manifestations include bilateral and symmetrical sensory
disorders, rarely motor disorders or dysautonomia. Symptoms are distal paresthesia and
hyperesthesia that initially affect the toes, sometimes the fingers, and that may extend
proximally. Trembling is common but usually doesn`t affect daily activities. Later vibratory
sensitivity and proprioception may be affected, leading to progressive ataxia, difficulty in
walking and trembling when posture is maintained (Cavaletti and Marmiroli, 2010; Mohty et
al, 2010).
The overall incidence of thalidomide-induced peripheral neuropathy ranges from 25 to 83 %,
of which two thirds is grade 1 to 2 and one third grade 3 to 4. Approximately 15 % of the
patients interrupt thalidomide treatment due to neuropathy (Mohty et al, 2010). In a meta-
analysis of 42 phase II trials of single thalidomide in 1674 relapsed or refractory multiple
myeloma patients, the incidence of grade 3 to 4 peripheral neuropathy was 6 % (Mohty et al,
2010). The neurological complications usually occur after prolonged exposure: 70 % of the
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patients treated for 12 months or more will develop peripheral neuropathy, which often limits
the dose and the duration of treatment (Cavaletti and Marmiroli, 2010). To minimize the risk
of irreversible neuropathy, thalidomide administration must be reduced or discontinuated
before the sensory neuropathy becomes painful, complicated by motor deficiency or
interferes with daily activities (Sioka and Kyritsis, 2009; Mohty et al, 2010).
Lenalidomide
Lenalidomide is an analogue of thalidomide with a better inhibition of TNF- and milder
neurotoxicity (Behin et al, 2008; Mohty et al, 2010). Neurotoxicity of oral lenalidomide
depends on a treatment schedule, 30 mg once a day being more toxic (23 %) than 15 mg
twice daily (10 %).  Only 3 % of patients developed grade 3 neuropathy. Pre-existing
thalidomide treatment seemed not to increase the risk of neurotoxicity. (Behin et al, 2008)
Prevention of CIPN
Prevention of CIPN by a concomitant agent would be a worthy option to enable effective
cancer treatment with neurotoxic chemotherapeutic agents. The ideal preventive treatment is
effective (i.e., it should prevent or slow the progression of CIPN), well tolerated, and not
compromising antitumor effect of the cancer treatment (Gamelin et al, 2004; Hochster et al,
2007). In spite of promising animal studies, no effective preventive agent with strong
evidence of its efficacy is available for clinical use.
Amifostine
Amifostine is an organic thiophosphate that acts as a scavenger of oxygen free radicals and
shows selective protection for normal tissues against toxicities induced by radiation,
alkylating agents and platinum compounds (Ocean and Vahdat, 2004; Kaley and Deangelis,
2009; Albers et al, 2011). Four randomized controlled studies (541 total participants) have
been performed in prevention of neurotoxicity: cisplatin for advanced head and neck
(Planting et al, 1999), paclitaxel and carboplatin for non-small cell lung cancer (Kanat et al,
2003), paclitaxel and carboplatin for ovarian cancer (Lorusso et al, 2003) and cisplatin and
cyclophosphamide for advanced ovarian cancer (Kemp et al, 1996). One of these trials
reported benefit of amifostine in neuroprotection (Planting et al, 1999).  In all studies patients
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randomized to the amifostine groups received intravenous amifostine immediately before
chemotherapy at doses of 740 mg/m2 or 910 mg/m2, and chemotherapy was given either
weekly or every three weeks up to six cycles (Kaley and Deangelis, 2009; Albers et al,
2011). There was no equal or standardized neurological examination scale among these
studies; different clinical scales based on descriptions of conventional neurological
symptoms or signs (Planting et al, 1999; Kanat et al, 2003; Lorusso et al, 2003), activities of
daily living (Kanat et al, 2003) or NCIC-CTC (Kemp et al, 1996) were used. None of these
four trials clearly masked the participant or the observer (Albers et al, 2011). According to
the results published so far the clinical benefit of amifostine is still unclear in spite of some
positive effects (Hensley et al, 2009; Albers et al, 2011). Because several of amifostine
studies used a combination of carboplatin and paclitaxel, the American Society of Clinical
Oncology panel extended recommendation against using amifostine for prevention of
platinum-associated neurotoxicity or ototoxicity or prevention of neuropathy caused by
paclitaxel or cisplatin (Hensley et al, 2009).
Acetyl-L-carnitine
Acetyl-L-carnitine has an essential role in intermediary metabolism including neuroprotective
and neurotrophic actions, antioxidant activity, positive actions on mitochondrial metabolism,
and stabilization of intracellular membranes (de Grandis, 2007). Acetyl-L-carnitine improves
non-oncological neuropathies (Bianchi et al, 2005). All patients except one reported
symptomatic relief in a pilot study with oral acetyl-L-carnitine (1 g twice a day) for 8 weeks in
25 patients with severe neuropathy (grade 3 or persisting grade 2) during paclitaxel or
cisplatin therapy. The sensory neuropathy grade improved in 60 %, and motor neuropathy in
79 %. (Bianchi et al, 2005)  No significant difference was found in overall peripheral
neuropathy incidence between treatment groups in the randomized placebo-controlled
REASON study in prevention of sagopilone-induced neuropathy with acetyl-L-carnitine (1 g
twice a day) in 150 ovarian and prostata cancer patients. However, the incidence of high-
grade neuropathy in the ovarian cancer patients was significantly lower in the acetyl-L-
carnitine group than in the placebo group (grade 2 35 % vs. 19 %, grade 3 20 % vs. 38 %) in
subanalyses (Lhomme et al, 2011). Further data is needed to validate these results.
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Vitamin E
Alpha-tocopherol is the most common lipid-soluble, chain-breaking antioxidant in the body
and it protects the integrity of membranes by inhibiting lipid peroxidation. A primary
mechanism of chemotherapy-induced toxicity is the formation of reactive oxygen species or
free radicals. Antioxidants may protect against neurotoxicity by bonding to free radicals and
preventing oxidative damage. Although the mechanism of vitamin E-mediated
neuroprotection is not entirely known, there are some similarities between clinical and
neuropathological aspects in peripheral neuropathy induced by cisplatin and vitamin E
deficiency (Sioka and Kyritsis, 2009; Kaley and Deangelis, 2009; Kottscahde et al, 2011). In
addition, during cisplatin therapy serum levels of vitamin E have been decreased. (Sioka and
Kyritsis, 2009; Albers et al, 2011; Wolf et al, 2008)
In a randomized pilot study of 47 patients alpha-tocopherol 300 mg/day before and during
cisplatin treatment and afterwards for 3  months, a significantly decreased incidence of
peripheral neuropathy was seen (31 % vs. 86 %) (Pace et al, 2003). These results were later
repeated in a randomized double-blind study of 108 cisplatin-treated patients. In that study
alpha-tocopherol was given 400mg/day. The incidence of neurotoxicity was significantly
lower in the vitamin-E group than in the placebo group (6 % vs. 42 %), and the severity of
neurotoxicity (measured with TNS) was significantly lower in the vitamin E group than those
receiving placebo (mean TNS 1.4 vs 4.1). (Pace et al, 2010)
In another phase III randomized double-blind placebo controlled trial of 207 patients vitamin
E 400 mg twice daily did not make any difference in the incidence of grade 2 sensory
neuropathy (Kottschade et al, 2010). Thus, the results are still inconclusive and there is
concern that supplemental antioxidant might interfere with the oxidative breakdown of
cellular DNA and cell membrans necessary for cytotoxic agents to work. (Wolf et al, 2008)
Carbamazepine and oxcarbazepine
Altered sodium channel inactivation kinetics has been shown in rat sensory nerves in the
development of acute neuropathy during oxaliplatin administration. Carbamazepine, a
sodium channel blocker, could therefore be an antagonist drug. Carbamazepine should,
however, be given before the first dose of oxaliplatin because channel inactivation kinetics
cannot be reversed by washout of oxaliplatin. (von Delius et al, 2007)
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A pilot study of 40 patients showed that oxaliplatin-induced sensory neuropathy may be
prevented by carbamazepine; carbamazepine pretreated patients reached significantly
higher cumulative oxaliplatin doses (Lerch et al, 2002). However, in a randomized controlled
study of 36 patients carbamazepine 200 mg did not prevent neurotoxicity; no significant
differences in grade 3 and 4 neurotoxicity were found. (von Delius et al, 2007)
Oxcarbazepine blocks sodium currents, but it also modulates different types of calcium
channels avoiding metabolites causing adverse effects. In a randomized, open-label,
controlled trial of 32 patients with colon cancer treated with FOLFOX-4 the incidence of
neuropathy was lower in patients receiving oxcarbazepine 600mg twice daily (31 % vs. 75
%) (Argyriou et al, 2006). The trial was rather small and open, which reduces its value (Wolf
et al, 2008)
Thus the evidence of carbamazebine and oxcarbazine in prevention of CIPN is still lacking.
Xaliproden
Xaliproden is an orally active, non-peptide neurotrophic and neuroprotective 5-HT (1A)
receptor agonist. It increases the expression of neurotrophins such as nerve growth factor,
brain derived neurotrophic factor, and neurotrophin 3, and acts on the development and
repair of neurons. In a prospective, randomized, double-blind placebo controlled phase III
study of 649 patients with metastatic colorectal cancer who were treated with oxaliplatin and
xaliproden (1 mg/day) no overall reduction of neurotoxicity was seen, but 5 % of patients
were shifted from grade 3 to grade 2 neurotoxicity.  The use of xaliproden was neither
associated with a higher cumulative oxaliplatin-dose nor a longer time on therapy. (Wolff et
al, 2008)
45
Glutamine
Glutamine is a nonessential amino acid. Glial cells release glutamine, which is then taken up
into presynaptic terminals and metabolized into glutamate by glutaminase (a mitochondrial
enzyme). Glutamate is an important neurotransmitter that plays a key role in long-term
potentiation and is important for learning and memory. (Vahdat et al, 2001; Amara, 2008;
Ocean and Vahdat, 2004; Kaley and Deangelis, 2009)
As a neuroprotective agent glutamine was studied in two pilot trials. One trial estimated the
impact of oral glutamine on high-dose paclitaxel-induced peripheral neuropathy (paclitaxel
825 mg/m2 over 24 hours) (Vahdat et al, 2001). Twelve patients were given oral glutamine
10 g 3 times a day for 4 days, beginning 24 hours after the completion of paclitaxel and 33
did not receive glutamine. In the glutamine group there were significantly fewer moderate-to-
severe dysesthesias, numbness and fewer abnormal gait, reduction of vibration sense in the
toes, motor weakness and less interference with ADL compared with non-glutamine patients.
However, all these toxicities were reversible over time. The result of another small study of
46 patients was in line with the previous one (Stubblefield et al, 2005). In the third
randomised, open label trial of 86 oxaliplatin treated patients with metastatic colorectal
cancer oral glutamine was given as 15 g twice daily for seven consecutive days every 2
weeks following oxaliplatin infusion. Patients with glutamine had significantly fewer
symptoms and interference with ADL: grade 3 to 4 neuropathy after four cycles (5 % vs. 18
%) and six cycles (12 % vs. 32 %), and the glutamine group needed fewer oxaliplatin dose
reductions. There were no significant differences in response rate to oxaliplatin or median
survival time. (Wang et al, 2007)
All three clinical trials specified that oral glutamine prevents various common signs and
symptoms of CIPN. However, the studies were small and none of them were placebo-
controlled. Glutamine was well tolerated. However, glutamine may increase the  risk  of
seizures and reduce the efficacy of antiepileptic medications. Further placebo-controlled
trials are necessary. (Amara, 2008; Wolf et al, 2008)
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Glutathione
A naturally occurring tripeptide glutathione has a high affinity for heavy metals and in animal
models it has been shown to decrease accumulation of platinum in the DRG (Pachman et al,
2011).
There are altogether six prospective, randomised placebo controlled studies of a total of 354
participants. Three of them used cisplatin for ovarian cancer, one cisplatin for non-small cell
lung cancer and head and neck cancer and two trials oxaliplatin for colorectal cancer. The
glutathione dose varied from 1.5 g/m2 to 5 g before chemotherapy. (Pachman et al, 2011;
Albers et al, 2011) Five studies reported a significant protective effect of glutathione.
However, the data  is insufficient to make any conclusions given the variable dosages used
with different malignancies, different combinations of chemotherapies, limited statistics, and
lack of long-term follow-up. (Albers et al, 2011)
 Org 2766
The peptide Org 2766 is a synthetic ACTH (4–9) analogue devoid of the adrenocorticotropic
and melanotropic effects. In preclinical tissue culture studies Org 2766 has delayed or even
prevented cisplatin induced neuropathy without causing side effects or interfering with
oncological activity. It promoted neurite outgrowth in the absence of nerve growth factor.
(Albers et al, 2011)
There are three studies (188 Org 2766 treated participants and 123 controls) of Org 2766 in
prevention of neurotoxicity. Org 2766 was given subcutaneously from 0.25 to 4.0 mg/kg. The
combined data of three trials using the same measure found no significant group difference
in QST examination. The overall results are to be considered as negative, because the first
study suggesting a protective effect of Org 2766 was based on an inadequate statistical
analysis. (Albers et al, 2011; Pachman et al, 2011)
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Calcium and magnesium infusions
The strongest data in prevention of CIPN is from intravenous calcium and magnesium
infusions in oxaliplatin treated patients. Oxaliplatin acute toxicity has been hypothesized to
be related to the interference of oxalate, a metabolite of oxaliplatin and a calcium chelator,
with voltage-gated sodium channels (Pachman et al, 2011). Increasing concentration of
extracellular calcium facilitates sodium channel closing, and this decreases the oxaliplatin-
induced hyperexcitability of peripheral neurons. (Grothey et al, 2011)
In the first retrospective, non-randomised report of 96 patients with advanced colorectal
cancer who had received intravenous calcium gluconate 1 g and magnesium sulphate 1 g
before and after oxaliplatin and 65 control patients the median cumulative administered
oxaliplatin dose was 910 mg/m2 in the Ca/Mg group compared with 650 mg/m2 in the control
group. In the Ca/Mg group 4 % of patients discontinued chemotherapy due to neurotoxicity
compared to 31 % of the control group. Patients receiving Ca/Mg did not suffer
laryngopharyngeal dysaesthesia whereas 9 % of the control patients did. At the end of the
study 27 % of the Ca/Mg group vs 75 % of the control group had signs of neurotoxicity of
any grade. Grade 3 neurotoxicity was less frequent in the Ca/Mg (8 % vs. 20 %) than in the
control group. (Gamelin et al, 2004)
Thereafter, three randomized placebo controlled trials have repeated these results (Grothey
et al, 2011). In the first study (N04C7) significantly less grade 2 or greater neurotoxicity was
found in Ca/Mg group than in the placebo group (22 % vs. 41% by the NCI-CTC, and 28 %
vs. 51 % by the oxaliplatin neuropathy scale), but no effect on acute cold-induced sensory
neuropathy was seen (Grothey et al, 2011). In the second study (CONcePT) final results are
not yet available. Finally, in a preliminary report of the third study (French Neuroxa ) a
significantly lower frequency and grade of oxaliplatin neurotoxicity was found in Ca/Mg group
(5 % vs. 24 % grade 3 NCI-CTC). (Gamelin et al, 2008; Grothey et al, 2011)
There have been some concerns of the safety of Ca/Mg infucions. In the interim analyses of
the CONcePT trial (N=174) oxaliplatin response rate was impaired in Ca/Mg group. Thus the
CONcePT trial and also N04C7 (N= 104 of 300 planned) and phase II Asian trials were
prematurely interrupted. Afterwards the response rate by an independent blinded radiologic
review of radiologic scans was actually higher in the Ca/Mg group than in the placebo group
(Grothey et al, 2011). In French Neuroxa study there was no affect on the oxaliplatin
responce rate (Gamelin et al, 2008).
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So far, there is still lack of consensus whether Ca/Mg infusions are truly effective as
neuroprotective agent against oxaliplatin-induced sensory neurotoxicities. (Grothey et al,
2011)
Melatonin
Melatonin, a pineal hormone, has been examined as a neuroprotective drug in preclinical
and clinical studies. It is suggested that melatonin inhibits the production of free radicals,
which play a role in mediating the toxicity of chemotherapy. There are only few preliminary
reports available of melatonin in prevention of CIPN with some postive results. (Lissoni et al,
1997a; Lissoni et al, 1997b)
In an open label, phase II pilot study of 22 breast cancer patients initiating taxane
chemotherapy with melatonin (21 mg/day) neuropathy was seen in 46 % (10 patients).
Twentythree  % (5 patients) had grade 1 and 23 % (5 patients) had grade 2 neuropathies
(Nahleh et al, 2010). No grade 3 or 4 neuropathy was reported. In another pilot study of 80
patients neuropathy was less frequent in patients treated with melatonin. The effectiveness
of chemotherapy was not altered by the addition of melatonin. (Lissoni et al, 1997a)
In line with previous two pilot studies, a randomized study of 70 patients with non-small cell
lung cancer patient receiving cisplatin and etoposide, melatonin 20 mg daily showed
significant reduction in  the  frequency of neuropathy (0/34 vs. 5/34 patients). There was no
impact on the effectiveness of the chemotherapy regimen, on the contrary, the one year
survival for patients receiving melatonin was better. (Lissoni et al, 1997b; Nahleh et al, 2010)
Other agents
In animal studies erythropoietin has showed neuroprotective and neurotropic effects and
efficacy in the prevention and treatment of CIPN, mostly in cisplatin-induced neuropathy.
However, the concern of the safety of erythropoietin in cancer treatment should be taken
seriously. (Pachman et al, 2011)
Neurosteroid allopregnanolone, also known as 3,5-tetrahydroprogesterone, is a
metabolite of progesterone and it interacts with various receptors and channels, including
GABA-A receptors and calcium channels. Allopregnanolone has neuroprotective,
neurogenic, and analgesic effects. In two animal studies the animals treated with
neurosteroids had lesser alterations in peripheral nerves, such as nerve conduction velocity
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and pain-transmission abnormalities.  The safety of using neurosteroids in patients with
hormone-dependent cancers is unknown. (Pachman et al, 2011)
A calcium channel antagonist nimodipine has been reported to have neuroprotective activity
in animal studies. However, in a pilot study of 50 patients treated with cisplatin no
neuroprotective effect was seen. (Pachman et al, 2011)
In a phase II randomized controlled prevention study the recombinant human leukemia
inhibitory factor did not succeed to show any benefit in patients treated with
carboplatin/paclitaxel (Pachman et al, 2011).
Diethyldithiocarbamate has been reported to block cisplatin-induced toxicity in animal
studies. However, in a clinical study of 221 cancer patients there was no significant
neuroprotective effect of diethyldithiocarbamate (Gandara et al, 1995). The data suffers from
having no measures of neurotoxicity other than subjective reporting (Albers et al, 2011).
The anticonvulsant valproate showed efficacy in cisplatin-treated rats and was associated
with improved sensory-nerve conduction velocity and DRG neuronal survival (Pachman et
al, 2011). No clinical trials are available.
Interleukin-6 is a cytokine that has been investigated in animal models for prevention and
treatment of diabetic neuropathy and CIPN in animal models (Pachman et al, 2011).
Several studies of the efficacy of antioxidants or their combinations have been done, but no
effect has been proven so far. (Albers et al, 2011; Kaley and Deangelis, 2009; Velasco and
Bruna, 2010; Botez and Hermann, 2010; Pachman et al, 2011)
Treatment of CIPN
There is no standard treatment of CIPN, unless it involves pain. So far, there are no
treatments that have been shown to be efficacious in randomized controlled trials. On the
basis of pathophysiological mechanisms, potential therapeutic targets for treatment of CIPN
would be sodium channels, calcium channels, TRPV1, gamma amino butyric acid receptors,
serotonin and norepinephrine receptors, N-methyl-D-aspartate receptors, and -receptors.
(Pachman et al, 2011)
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Acetyl-L-carnitine
According to animal studies acetyl-L-carnitine could be effective in prevention and/or
treatment of paclitaxel-induced peripheral neuropathy. In a pilot trial of 25 patients with grade
3 neuropathy from paclitaxel or cisplatin, acetyl-L-carnitine showed some positive effect, but
further studies are needed. (Bianchi et al, 2005; Ocean and Vahdat, 2004; Kaley and
Deangelis, 2009; Cavaletti, 2009; Pachman et al, 2011; Albers et al, 2011)
Alpha-lipoic acid
Alpha-lipoic acid is an antioxidant produced naturally by the body. It is included in some
foods and in nutritional supplements. In vitro studies have shown alpha-lipoic acid protecting
sensory neurons through its anti-oxidant and mitochondrial regulatory functions (Melli et al,
2008). Four-year treatment with alpha-lipoic acid in mild-to-moderate diabetes-induced
neuropathy reportedly leads to a clinically meaningful improvement and prevention of
progression of neuropathic impairments while being well tolerated (Ziegler et al, 2011).
There is a phase II trial ongoing in breast cancer patients treated with paclitaxel. (Melli et al,
2008; Pasetto et al, 2006)
Anticonvulsants: gabapentin, pregabalin and lamotrigine
Anticonvulsants are commonly used in painful diabetic neuropathy, nerve injury pain, PHN,
trigeminal neuralgia, phantom limb pain. Gabapentin provides significant pain relief
approximately for a third of the patients with painful neuropathy. The most common side-
effects are dizziness, somnolence, peripheral oedema, and gait disturbance. (Moore et al,
2011)
The most commonly used anticonvulsants are gabapentinoids, gabapentin and pregabalin.
Gabapentinoids bind on 2 subunit of presynaptic, voltage-gated calcium channels
reducing calcium influx and neurotransmitter release from damaged hyperexcited neurons.
(Moore et al, 2011)
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In a double-blind placebo-controlled trial of 115 patients with CIPN gabapentin (target dose
900 mg three times a day) for 6 weeks did not significantly improve the pain relief or the
ECOG toxicity rating for sensory neuropathy (Rao et al, 2007).
In animal studies intraperitoneally given pregabalin has caused a significant reduction of the
vincristine induced allodynia (Nozaki-Taguchi et al, 2001). In a small study of 23
gastrointestinal cancer patients with grade 2 and 3 oxaliplatin-induced sensory neuropathy
pregabalin (target dose of 150 mg three times a day) reduced the neuropathy to grade 1-2 in
48 % of the patients (Saif et al, 2010). The target dose provided the best benefit, but there
was some efficacy at lower doses also (Pachmann et al, 2011).
Lamotrigine failed to demonstrate any significant impact on neuropathic pain in a study of
125 patients with oxaliplatin induced neuropathic pain. (Rao et al, 2007; Wiffen et al, 2011)
Antidepressants: tricyclic agents, duloxetine and venlafaxine
In the treatment of neuropathies, especially in diabetic neuropathy and PHN, tricyclic
antidepressants are the most effective and widely used antidepressants (number needed to
treat 3,60, 95 % CI 3 to 4.5) (Saarto and Wiffen, 2010). Amitriptyline has been shown to be
superior  to placebo in treatment of diabetic neuropathy (Max, 1987), postherpetic neuralgia
(Graff-Radford et al, 2000), and postoperative neuropathic pain in breast cancer patients
(Kalso et al, 1996). There are also some new data on venlafaxine and duloxetine in the
treatment of neuropathic pain (Saarto and Wiffen, 2010, Durand et al, 2011; Bril et al, 2011).
Duloxetine hydrochloride is a balanced SNRI used in the treatment of major depression. Its
efficacy is established by three large-scale trials in diabetic painful polyneuropathy (Attal et
al 2010). Duloxetide is approved by the FDA for the management of diabetic peripheral
neuropathy and fibromyalgia, as well as for depression and anxiety. (Yang et al, 2011) In a
single-arm open-labeled pilot study of 39 patients with stage III or IV colorectal cancer and
chronic oxaliplatin-induced neuropathy duloxetine (30 - 60 mg/day) improved VAS score in
19 patients (63 %), among them, nine (47 %) patients showed a simultaneous improvement
in NCI-CTC neurotoxicity grade (Yang et al, 2011). However, nine patients (28 %)
discontinued duloxetine because of adverse events, including dizziness/giddiness/nausea,
somnolence, restlessness or insomnia and urinary hesitancy.  There is an ongoing phase III
double blind trial of oral duloxetine for treatment of pain associated with CIPN
(http://clinicaltrials.gov). Of note, duloxetine is a potent cytochrome P450 2D6 inhibitor, and
hence it might interfere with other drugs metabolized via same pathway (e.g., tamoxifen).
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Duloxetine has been reported to lower the plasma concentration of endoxifen, the active
form of tamoxifen (Yang et al, 2011; Pachman et al, 2011).
Venlafaxine is a SNRI antidepressant with reported efficacy for painful neuropathies of
various ethiologies (Pachman et al, 2011).  In treatment of various neuropathies venlafaxine
has been shown to have pain-relieving effects only at high doses (150–225 mg/day), when
noradrenergic effect is more predominant and accompanied with more side effects, too
(Pachman et al, 2011).
In a randomized, double-blind, placebo-controlled phase III trial (EFFOX) of 48 cancer
patients with oxaliplatin-induced acute neurotoxicity venlafaxine 50 mg or placebo was given
orally one hour prior to oxaliplatin infusion and extended-release venlafaxine 37.5 mg or
placebo twice a day from day 2 to day 11. In the venlafaxine group there was significantly
less acute neurosensory pain than in the placebo group (35 % vs. 77 %). Full relief of pain
(measured by NRS) was reported in 31 % of the patients in venlafaxine arm vs. 53 % in the
placebo arm. The most common side effects of venlafaxine are somnolence, nausea,
asthenia, and at higher doses hypertension may occur. (Durand et al, 2011)
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AIMS OF THE PRESENT STUDY
In patients treated with neurotoxic chemotherapy, the present study aimed to investigate:
1. The prevalence and discomfort of neurotoxicity in relation to other adverse effects of
chemotherapy (I)
 2. The effect of amitriptyline in treatment of chemotherapy-induced peripheral neuropathic
symptoms compared with placebo (II)
3. The effect of amitriptyline in prevention of chemotherapy-induced pheripheral neuropathic
symptoms compared with placebo (III)
4. Two different neurotoxicity scales (the National Cancer Institute-Common Toxicity Criteria
and oxaliplatin scales) in grading of chemotherapy-induced peripheral neurotoxicity (IV)
5. The changes in intraepidermal nerve fiber density during neurotoxic chemotherapy (V)
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PATIENTS AND METHODS
Patients
The study included three patient populations (studies I-II, studies III-IV and study V) of
cancer patients treated with neurotoxic chemotherapy at Helsinki University Hospital,
Department of Oncology (studies I-IV) and Gynecology (studies III-IV) and Department of
Oncology, Tampere University Hospital (study V).
Studies I-II
The screening prosess of the studies I and II is presented in Figure 3. Inclusion criteria were
age 20 to 65 years, life expectancy of at least three months, planned duration of
chemotherapy at least two months, intensity of neuropathic symptoms (numbness, tingling or
pain) at least 3 measured with a numerical rating scale (0-10). Exclusion criteria were
neurological disease confusing assessment of symptoms, other possible causes of
neuropathy, any contraindication for amitriptyline, use of medication for neuropathic
symptoms, use of medication which inhibits noradrenalin reuptake, pregnancy and lactation.
Patient recruitment for the study II was terminated earlier as planned due to low recruitment
rate. With permission of the Ethics Committee of the Helsinki University Central Hospital the
sample size was reduced to 45. Eventually, 44 patients with advanced cancer were
randomly allocated into the study, 22 subjects in both groups. This 8-week double-blind,
randomized, placebo-controlled parallel group study was performed between January 2002
and August 2004.
Studies III-IV
Inclusion criteria were age 18 to 75 years, life expectancy of at least three months, planned
duration of chemotherapy at least two months and absence of previous neuropathy.
Exclusion criteria were the same as for the study II. For the study III, 123 consecutive
patients without previous neuropathy, who started their first neurotoxic chemotherapy with
vinca alcaloids, platinum derivatives, taxanes or a combination of several neurotoxic agents,
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were randomized. Of them, 24 patients were excluded from the final analyses (5 due to
disease confusing the assessment of neuropathic symptoms, 4 because of multiple lines of
chemotherapy and 15 because of not returning the diaries). Hence, 99 patients were
included in the final analyses. The study was performed between February 2003 and May
2006.
56
Figure 3. The screening prosess of the studies I and II.
Study I
Screened patients
N=448
 1/2002-6/2004
 Respondents
     N=338 (75 %)
Non respondents
          N=110 (25 %)
No symptoms
N=80 (24 %)
Neuropatic symptoms
N=258 (76 %)
Final population for the study I and
screening population for the study II
N=152 (59 %)
Study II
N=44
 1/2002-8/2004
Amitriptyline N=22
Placebo N=22
Excluded
n=11 (25 %)
 1 died before starting
 1 withdrew before starting
 3 withdrew due to adverse
effects*
 4 chemotherapy interrupted
 2 were noncompliant
Final population
N=33 (75 %)
Amitriptyline N=17
Placebo N=16
Excluded
N=106 (41 %)
* all patients who withdrew due to side
effect were randomised to the placebo
group
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Study I
Final Population N=152
Study II
Final Population N=33
Study III
Final Population N=114
NPS present
N=90
NPS absent
N=62
Amitriptyline
N=17
Placebo
N=16
Amitriptyline
N=58
Placebo
N=56
Age, mean (range) 55 (31-70) 51(24-68) 52 (37-67) 54 (35-67) 55 (25-74) 57 (26-75)
Gender, N (%)
Male
Female
23 (26)
67 (74)
14 (23)
48 (77)
3  (18)
14 (82)
5 (31)
11 (69)
19 (33)
39 (67)
13 (23)
43 (77)
Diagnosis N (%)
   Breast cancer
   Colorectal cancer
   Lymphoma
   Melanoma
   Lung cancer
   Ovarian cancer
   Other malignancies *
46 (51)
18 (20)
17(19)
3 (3)
0
3 (3)
37 (60)
8 (13)
6 (10)
2 (3)
0
7 (11)
10 (59)
3 (17)
1 (6)
0
1 (6)
0
2 (12)
10 (63)
4 (25)
2 (12)
0
0
0
0
5 (9)
9 (16)
9 (16)
0
0
23 (40)
4 (7)
3 (5)
6 (11)
9 (16)
0
0
27 (48)
3 (5)
Chemotherapy
agent N (%)
   Vinca-alkaloids
   Platinum derivatives
   Taxanes
   Combination
42 (47)
23 (25)
25 (28)
0
26 (42)
17 (27)
19 (31)
0
6 (35)
5 (29)
5 (29)
1 (6)
6 (35)
34 (25)
5 (31)
1 (6)
12 (25)
16 (28)
4 (7)
26 (45)
12 (21)
10 (18)
3 (5)
31 (55)
Current chemo-
therapy N (%)
    Adjuvant
   First-line
   Second-line
  Third-line
   Fourth-line
23 (26)
34 (38)
33 (36)
0
0
17 (27)
24 (39)
21 (34)
0
0
0
13 (76)
 2 (12)
 1 (6)
1 (6)
0
11 (69)
 4 (25)
 1 (6)
 0
24 (41)
26 (45)
  8 (14)
0
0
26 (46)
28 (50)
 2 (4)
0
0
NPS, neuropathic symptoms
 *only in study I
Table 4. Clinical characteristic of the patients in studies I-III.
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Study V
The study population consisted of 12 cancer patients aged from 18 to 70 years and starting
their first adjuvant chemotherapy with platinum derivatives or taxanes. The same exclusion
criteria were applied as in the studies II and III.
Methods
Assessment of neuropathic symptoms
A questionnaire of neuropathic symptoms was used in the screening for the studies I and II.
It included questions about presence of numbness, tingling, pain or impaired sensory
function in hands and/or feet, clumsiness in fingers, peripheral muscular weakness or
difficulties in walking, and the patients replied with yes/no answers.
In the studies II and III the intensity of the neuropathic symptoms and the global disturbance
of them during the treatment were assessed with a VAS scale (0–100 mm) using a diary. It
was filled twice a week during the whole study period.
The severity of sensory and motor neuropathy was graded according to the NCI-CTC scale
(studies II, III and IV) and the oxaliplatin scale (studies III and IV).
Assessment of global improvement
In the study II, the patients assessed global improvement of the neuropathic symptoms with
a VAS scale (0–100 mm) in the diary twice a week during the whole study period. In
addition, on the final visit, they assessed the global improvement of the neuropathic
symptoms using a 5-point VRS (complete relief, moderate relief, some relief, no change,
worse symptoms).
Assessment of chemotherapy-induced toxicity other than neurotoxicity
Other adverse effects of chemotherapy but neuropathy were assessed by the NCI-CTC
scale (studies II, III and IV) and a questionnaire including the most common chemotherapy
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adverse effects (fatigue, nausea and vomiting, constipation, sweating, odema, alopecia,
mucositis, eye symptoms, changes of taste and an open question of any other possible
chemotherapy-related symptom) (studies I, II and III). Patients were asked to name the most
troublesome chemotherapy-induced symptom (study I).
Physical examination
Neurological examination was performed by the study physician at every visit (studies I, II, III
and V). The neurological examination included motor assessment (muscle strength in the
limbs), sensory testing (examination of touch, pinprick, cold, warm, vibration and position
sense and testing of allodynia for dynamic and static mechanical stimuli), testing of balance,
co-ordination, fine motoric performance and deep tendon reflexes.
Blood samples and electrocardiogram
Blood samples (serum creatinine, transaminases, glucose, free T4, TSH and vitamin B12)
were taken to exclude other causes of neuropathy in the studies II, III and V.
Electrocardiogram was taken to exclude cardiac contraindications to amitriptyline in the
studies II and III. A blood sample for analysis of the concentration of amitriptyline was taken
at 8 weeks’ visit in the studies II and III.
Randomization and blinding
In the studies II and III a computer generated randomization schedule was used to allocate
the patients to either the amitriptyline or the placebo group by the hospital pharmacy.  In the
studies II and III the randomization was stratified according to the chemotherapy group and
the diagnosis. Both patients and clinicians were blinded during the whole treatment period.
Study medication
The hospital pharmacy provided identical capsules of either placebo or amitritpyline.
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In the study II the treatment was started with one 10mg drug capsule or placebo at bedtime.
Dose elevation was 10 mg per week up to the target maximum dose of 50 mg/day if
tolerated. In case of intolerable adverse effects dose escalation was terminated and the
dose was reduced by 10 to 25 mg, if necessary. The total treatment time was 8 weeks.
In the study III the treatment was started with one 25 mg drug capsule or placebo at
bedtime. Dose elevation was 25 mg per week up to the target maximum dose of 100 mg/day
if tolerated. In the case of intolerable adverse effects, dose escalation was terminated and
the dose was reduced by 25 mg, if necessary. The treatment was continued until the end of
the neurotoxic chemotherapy.
Assessment of quality of life and depression
QoL was assessed with the EORTC-C30 questionnaire for cancer patients in the studies II
and III. Depression was evaluated using the emotional functioning subscore of the EORTC-
C30.
Assessment of activity of daily living, physical activity and sleep
ADL was assessed at every visit with a 6-item questionnaire including questions about
eating, clothing, washing, brushing the teeth, shaving and combing the hair. Physical activity
was inquired at every visit with a 4-item questionnaire including questions about physical
performance, physical activity, house keeping and hobbies. These questionnaires used
grading to normal, mildly impaired and severely impaired. The assessment of sleep included
questions about the duration of sleep and the number of awakenings. These questionnaires
were used in the studies II and III.
Assessment of side-effects of the study medication
The side effects of the study medication were queried in the diary with an open question,
and the intensity of them was scored with a five-point verbal scale (none, mild, moderate,
severe, untolerable) in the studies II and III.
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Skin biopsy
In the study V, skin biopsies (diameter 3 mm) were taken at every study visit from the right
distal leg 10 cm above the lateral malleolus. Specimens were fixed in 10% formalin and then
embedded in paraffin. Ten-m sections were immunostained with a polyclonal panaxonal
marker PGP 9.5.  The number of IENF was counted with a light microscope at 400 x
magnification blinded to the clinical status of the patients. Three adjacent skin sections were
analyzed to get proper estimation of IENF count. For the estimation of epidermal area the
point-counting was performed using square lattice. The normal value for IENF density was
considered as more than 40 fibres per mm2 (Koskinen et al. 2005).
62
Table 5. Methods.
Study I Study II Study III Study IV Study V
Neuropathic
symptoms
Screening
questionnaire,
VAS
VAS (diary)
Global
improvement
VAS (diary) History of
symptoms at
every study visit
Grading of
neuropathic
symptoms
NCI-CTC NCI-CTC
Oxaliplatin scale
NCI-CTC
Oxaliplatin scale
Global improvement
of neuropathic
symptoms
VAS (diary)
VRS
Clinical
examination
At the
screening visit #
At every study
visit
At every study
visit
At every study
visit
ADL, physical
activity, sleep
Questionnaire Questionnaire
QoL EORTC-C30 EORTC-C30 EORTC-C30
Chemotherapy
toxicity
Questionnaire
Naming the most
troublesome side
effect
Questionnaire
NCI-CTC
Questionnaire
NCI-CTC NCI-CTC
Side effects of the
study medication
Questionnaire
(diary)
Questionnaire
(diary)
Laboratory tests At screening:
TSH, T4V,
vitamin B12 ,
glucose
Amitriptyline
concentration
At screening:
TSH, T4V,
vitamin B12,
glucose
Amitriptyline
concentration*
At screening:
TSH, T4V,
vitamin B12,
glucose
Skin biobsy
every 3rd cycle
STATISTICAL METHODS
Statistical analyses
Statistical analyses were performed using SPSS 12.0 for Windows.
Study I
Clinical characteristics of the two groups (patients with and without neuropathic symptoms)
were compared using t-test or chi-square test. The occurrence of chemotherapy-induced
symptoms and the most troublesome symptom in the two groups were analysed using age-
and sex-adjusted logistic regression models.  No adjustment was made for multiple testing,
# for symptomatic patients only
* results not reported
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but this information can be obtained by multiplying the actual p-value by the number of
comparison made.
Study II
Global improvement, severity of neuropathic symptoms, QoL, depression and anxiety were
tested by repeated-measures analysis of variance (ANOVA model) with treatment group as
grouping variable. Between and within groups comparisons were performed with T-test. The
planned study size was 120 patients. With permission of the Ethics Committee of the
Helsinki University Central Hospital the sample size was later resized to 45 with a
significance level of 0.05 and power of 0.80 to identify a 30 % difference between the
groups.
Study III
Analyses were performed on the intent-to-treat population, defined as all randomized
patients who returned their diaries at the follow-up visits. The last-observation-carried-
forward approach was used for missing data. Statistical comparison between groups was
made by using either t-test or chi-square test. The appearance and progression of
neuropathic symptoms was assessed with neuropathy score: the sum of the intensity of the
different symptoms (no=0, mild=1, moderate=2, severe=3) divided by ten, the score having a
theoretical range from 0 (no symptoms) to 3 (all ten symptoms graded as severe). The area
under the curve for neuropathy score was calculated with the trapezoidal method.
Permutation test was used to test differences between groups for side effects and bootstrap-
based multiplicity adjustment was applied to correct levels of significance for multiple testing.
QoL data were analyzed using generalizing estimating equations models with the
exchangeable correlation structure. Correlation coefficients were calculated by the
Spearman method.
The planned study size was 250 patients. This study was designed to have 125 patients in
each arm to provide 80 % power ( error, 0.05) to detect a 20 % change in symptom score,
which was regarded as a clinically significant change. According to the original protocol,
interim analyses were carried out when 120 patients had been randomized. Because of the
64
negative results in the interim analyses, recruitment was cancelled after 123 patients had
been randomized.
Study IV and V
These studies were descriptive. No statistical comparisons were made.
Ethical considerations
The studies were approved by the Ethics Committee of the Helsinki University Central
Hospital (studies I-IV) and Tampere University Hospital (V), and a written informed consent
was obtained from all participants.
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RESULTS
Burden of CIPN (study I)
At the screening visit, 90 out of 152 (59 %) patients who were treated with neurotoxic
chemotherapy reported neuropathic symptoms. Tingling (71 %), numbness (58 %), impaired
sensory function (46 %) and pain in hands and feet (40 %) were the most common
symptoms. The median intensity of neuropathic symptoms was 28/100 on the visual
analogue scale (0-100). Grading has been reported in Table 6.
Table 6. Grading of neuropathic sensory symptoms by NCI-CTC in the screening and
prevention populations (studies I and  III)
Grade
Screening
(152 patients)
% of patients
Prevention study
visit 2
(97 patients)
% of patients
Prevention study
visit 3
(79 patients)
% of patients
Prevention study
visit 4
(41 patients)
% of patients
0 41 % 39 % 44 % 24 %
1 13 % 56 % 35 % 39 %
2 25 % 3 % 18 % 20 %
3 22 % 2 % 3 % 17 %
4 0 % 0 % 0 % 0 %
In the whole cohort of 152 patients, fatigue (66 %), mucositis (61 %) and neuropathic
symptoms (59 %) were the most commonly reported symptoms. In addition, every third
patient (37 %) with neuropathic symptoms ranked them as the most troublesome symptom.
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Amitriptyline in prevention and treatment of CIPN (studies II, III)
Tolerability of amitriptyline
Amitriptyline was well tolerated both in the prevention and treatment studies (II, III). In the
treatment study (II) 15 patients out of 17 (88 %) reached the target dose and completed the
study. The daily dose was reduced from 30 to 10 mg in one patient because of tiredness  (6
%) and from 50 to 25 mg in another patient because of tachycardia (6 %). After the dose
reduction, the adverse effect disappeared but the neuropathic symptoms exacerbated in
both patients. There was no significant association between the severity of the side effects
and the drug concentration (study II). In the placebo groub three patients terminated the
study during the dose titration due to side-effects (16 %).
In the prevention study (III) 40 out of 54 patients (74 %) with amitriptyline reached the target
dose (100 mg). The dose was reduced to 25 mg in one patient and to 50 mg in 13 patients.
The most common reason for dose reduction was tiredness (n=11, 20.4 %). Dry mouth (2 %)
, visual disturbances (2 %)  and constipation  (2 %) caused dose reduction in one patient
each. In the placebo group the dose was reduced to 50 mg in 4 patients out of 45 because
of palpitation (2 %), dizziness (2 %), dry mouth  (2 %) and tiredness (2 %) in one patient
each. Dry mouth was more severe in the amitriptyline group both at the dose titration phase
(p<0.001) and stable dose phase (p<0.001). Tremor was more severe in the amitriptyline
group at the stable dose phase (p=0.034).
Prevention of CIPN (study III)
The intensity of neuropathy was mild in general (Figure 4b). There was no significant
difference between the amitriptyline and placebo groups in the intensity of the neuropathic
symptoms (Figure 4a).
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Figure 4a. Intensity of neuropathic symptoms.
Figure 4b. Intensity of neuropathic symptoms in amitriptyline and placebo groups.
In line with results of the neuropathic score, there was no significant difference in NCI-CTC
scoring between the amitriptyline and placebo groups. After 3, 6 and 9 chemotherapy cycles,
sensory neuropathy was seen in 61 % of the patients (57 % in the amitriptyline group and 65
% in the control group), 56 % (56 % and 56 %) and 76 % (67 % and 85 %), respectively, and
motor neuropathy in 26 % (22 % and 30 %), 36 % (32 % and 42 %) and 22 % (14 % and 30
%). Neuropathy was mild, grade 1, in the majority of the cases. (Table 6).
Treatment of CIPN (study II)
There was a trend towards better global improvement of the neuropathic symptoms with
amitriptyline assessed by the patients using VAS: after eight weeks, the mean VAS (± SD) for
global improvement was 3.4 ± 3.6 in the amitriptyline group and 1.9 ± 3.1 in the placebo
group, respectively. Global improvement measured by VRS demonstrated at least some relief
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of neuropathic symptoms in eight (47 %) and five (31 %) patients in the amitriptyline and
placebo groups, respectively, however, these differences were not statistically significant.
There was no statistically significant difference in the severity of the neuropathic symptoms
between the amitriptyline and placebo groups during the study. The disturbance of all
neuropathic symptoms was, in general, low: varying from 0 to 8.2 (mean 2.5) at baseline.
Paresthesia and tingling were the most common symptoms, reported by 25 out of 33 (76 %)
patients. Pain was present in 19 (58 %) and itching in 15 (45 %) patients.
According to the NCI-CTC scale, Grade I-II sensory neuropathy was found in 31 (70 %)
patients and Grade I-II motor neuropathy in 21 (64 %) patients. No Grade 3 or 4 neuropathy
was seen.
Amitriptyline improved QoL measured with the EORTC QLQ-C30 (global health score)
statistically significantly compared with placebo (P = 0.038). The improvement of QoL was
not related to either depression or sleep. The mean global health scores for the amitriptyline
and placebo treated patients were 48 and 62 at baseline, 62 and 54 after 4 weeks, and 55 and
49 after 8 weeks, respectively.
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Assesment (study IV)
The NCI-CTC sensory and the oxaliplatin scales were comparable in identifying neuropathic
symptoms. The oxaliplatin score was more sensitive at detecting changes in the progression
of the neuropathic symptoms compared with the NCI-CTC scale. The progression of the
toxicity from mild (grade 1-2) to moderate or severe (grade 3-4) was detected more
frequently with the oxaliplatin scale.
Of the patients with grade 3-4 toxicity by the oxaliplatin scale, 23/53 had grade 1 toxicity by
the NCI-CTC scale, 18/53 had grade 2 and 12/53 had grade 3 neurotoxicity. However, the
oxaliplatin scale was in line with the NCI-CTC scale in 12/13 patients with grade 3
symptoms.
Intraepidermal nerve fiber density (study V)
Reduced IENF density was found in 8 patients out of 12 at baseline and all of them had
normal sensory findings in clinical examination. During the follow-up, the IENF density
increased significantly in six of them and remained unchanged in two. In four patients the
IENF density was normal both at baseline and at the end of the follow-up period.
Neuropathic symptoms were manifested in nine patients, but no association with the IENF
count was found.
70
DISCUSSION
Prevalence and burden of chemotherapy-induced neuropathy
The prevalence of neuropathic symptoms varied depending on the chemotherapeutic
agents, treatment schedule, cumulative doses and study population. Symptoms were most
common in patients treated with vincristine (70 %), oxaliplatin (70 %) and paclitaxel (70 %).
Patients with and without neuropathic symptoms differed from each other by age (p=0.004).
Longitudinal follow up studies of the symptoms are lacking. The prevalence of neuropathic
symptoms (59 %) in the present cross-sectional study was, however, in line with previous
literature (Argyriou et al, 2011). In the present population neuropathic symptoms was the
third most common adverse effect of chemotherapy, when neurotoxic agents were used.
In the current study, albeit the neuropathic symptoms were common, their intensity was mild.
However, despite the low intensity, every third patient rated neuropathy, when present, as
the most troublesome symptom. This discrepancy could be related, at least partly, to
difficulty to score neuropathic symptoms other than pain. VAS is well documented in the
measurement of the intensity of neuropathic pain in diabetes and PHN. In CIPN, however,
tingling and numbness are the most common symptoms (Wolf et al, 2008). Similarly, in the
present study tingling and numbness were experienced approximately by two thirds of the
patients (71 and 58 %, respectively), while pain was only the fourth commonest symptom
reported by 40 % of the patients. VAS has not been widely used to measure the intensity of
CIPN symptoms so far. In a recent lonigitudinal study using VAS to assess CIPN, VAS was
found to be able to recognize difference between two neurotoxic treatment regimens and
catch the change in peripheral neuropathic symptoms. Interestingly, the authors noticed that
pain and numbness had separate patterns of appearance (Takemoto et al, 2011). Another
plausible explanation for the discrepancy between the intensity and inconveniency is the
chronic character of neuropathic symptoms, which can cause discomfort in daily life even
when it is mild and does not interfere with function, like tingling and numbness. The
difference in the sensory and affective dimensions of pain and other sensory symptoms may
also influence the result (Haanpää et al, 2011), but as we did not use McGill pain
questionnaire which is able to capture this we cannot analyze this hypothesis. The finding in
the present study of the low intensity but high inconvenience caused by neuropathic
symptoms highlights the importance of carefull measurement of neuropathic symptoms. This
is important as more cancer patients are exposed to neurotoxic agents.
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Assessment of chemotherapy-induced neuropathy
The analysis of the prevalence and severity of neuropathic symptoms caused by
chemotherapy is challenging as the patients often receive different types of
chemotherapeutic agents at different doses and for various cancers. Patients with advanced
cancer and numerous chemotherapy treatments have many other disturbing symptoms,
such as cancer-related pain, nausea, and fatigue, which also attract their attention and may
cause underrating of the severity of neuropathic symptoms. In addition, some patients may
be unwilling to report neuropathic symptoms that might lead to the cessation of
chemotherapy. The intensity of the symptom does not nessessarily correlate to functional
impairment, like capability to button a shirt. These features of patients with chemotherapy-
induced neuropathy make the comparison of neuropathic symptoms caused by
chemotherapy and other diseases, such as diabetes or herpes zoster, problematic.
To date, there is no agreement on the best way to assess the severity of CIPN. The method
should include assessment of symptoms, signs, functional ability and electrophysiological
findings. In clinical practice, assessment including symptoms and physical examination is
probably the most sensitive and reliable method of detecting CIPN because of lack of
reliable objective methods suitable for clinical use (Velasco and Bruna, 2010; Kaley and
Deangelis, 2009; Ocean, 2004; Cavaletti, 2011). Especially symptoms (clumsiness of the
hands or numbness or pain in the feet) and signs that influence daily living and QoL are
important. Careful instrumental technical methods are often available but they are time-
consuming and not always feasible in the clinic. They provide a quantitive estimate of
severity, but their principal role is in research (Velasco and Bruna, 2010; Cavaletti et al,
2011).
The role of patient-reported outcomes is increasing (Garcia et al, 2007). In chronic pain and
other troublesome symptoms, where the importance of a subjective symptom must be
considered against the background of the patient’s subjective values, patient-reported
outcome measures have particular weight. In clinical practice and also clinical research the
role of history of symptoms and their impact is hence crucial. Recently (after our study was
commenced) many patient-based assessment instruments such as the Functional
Assessment of Cancer Therapy/Cynecologic Oncology Group-Neurotoxicity (Huang et al,
2007), the QLQ-CIPN20 of the EORTC (Postma et al, 2005) and the Patient Neurotoxicity
Questionnaire (Shimozuma et al, 2009) have been published. However, the disadvantage of
these patient-based instruments seems to be that they are somewhat cumbersome to
administer (Takemoto et al, 2011). A recent systematic review concluded than currently
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there is little evidence to support for the hypothesis that disease-, symptom- or treatment-
specific instruments are more sensitive and responsive than cancer-specific or generic
questionnaires. However, the conclusions were limited by the small number of head-to-head
comparisons available (Luckett et al, 2010).
Grading of CIPN
The NCI-CTC scale is the most commonly used scale in rating neurotoxicity in oncology
(Argyriou et al, 2011; Carlson and Ocean, 2011). Scoring neurotoxicity by NCI-CTC is based
on whether the symptom interferes with function (grade 2), with ADL (grade 3), or whether
the symptom permanently interferes with function or causes paralysis (grade 4). Grades 3
and 4 represent severe symptoms and are commonly reported in chemotherapy trials. For
oxaliplatin neurotoxicity, a special grading system for the assessment of oxaliplatin-induced
paraesthesia/dysaesthesia by Levi (Lévi et al, 1992) has been conducted (Cavaletti et al,
2010). On the contrary to NCI-CTC scale the oxaliplatin scale is based on the duration of the
symptoms. Toxicity that does not disappear between the chemotherapy cycles is classified
as severe (grade 3). On both scales grade 4 toxicity includes permanent symptoms with
interference with function or ADL. There is, however, no consensus as to which factors, the
degree of functional impairment, or the continuity of the symptoms that are the most
important in determining the clinical severity of neuropathy. The reversibility of long-lasting
grade 3 neurotoxicity by oxaliplatin scale has been 74 % with a median time to recovery
within 13 weeks (de Gramont et al, 2000; Land et al, 2007). However, even after 18 months
of oxaliplatin-based chemotherapy 22 % of the patients reported numbness and tingling in
the feet, and after two years over 10 % of the patients still reported symptoms (Land et al,
2007). Such information is lacking from NCI-CTC-scale.
Park et al. compared the NCI-CTC and oxaliplatin scale in patients who were treated with
oxalipatin (Park et al, 2011). By completion of the treatment, 20 % of the patients had severe
chronic neuropathy (NCI-CTC grade 3), 51 % moderate (NCI-CTC grade 2) and 29 % mild
neurotoxicity (NCI-CTC grade 1). They found that the oxaliplatin scale demonstrated the
same distribution of grades of neurotoxicity severity as the NCI-CTC scale.
Likewise in the present population of chemotherapy-naïve patients who started neurotoxic
chemotherapy including also other neurotoxic drugs than oxaliplatin, the scales were equally
sensitive in detecting early neurotoxicity. However, there was a noticeable difference
between the scales in detecting the progression of neurotoxicity. The NCI-CTC sensory
73
scale classified neurotoxicity more often as mild (grade 1 to 2) while the oxaliplatin scale
showed incomplete regression of the symptom (grade 3 to 4). One plausible explanation for
this is the subjectivity of the NCI-CTC grading. In particular, the difference between grade 2
(interference of symptoms with function) and grade 3 (interference of symptoms with activity
of daily living) is not entirely objective. For example, clumsiness of hands does interfere with
function, but the interference with activity of daily living varies individually, depending on
patients’ age, performance status, profession, family, housing and leisure time activities. In
addition, patients may underestimate or, on purpose, under-report the discomfort of the
toxicity because they are worried of the future treatment options. This may explain, at least
partly, the lower rate of grade 3 neurotoxicity by the NCI-CTC. On the other hand, the
oxaliplatin scale is more objective as the grading is based on duration and continuity of the
symptoms. Thus, in the present population, the duration of the symptoms appears to be
more sensitive than the functional impairment reported by the patients in detection of
progression of neurotoxicity. The fact that the oxaliplatin scale more sensitively detected the
progression of neurotoxicity could be significant because early progression of neuropathic
symptoms might reflect more severe toxicity later in the chemotherapy course or neuropathic
pain later in life.
Similarly to the NCI-CTC sensory grading, the motor grading is subjective, too. Muscular
weakness is a common symptom of cancer patients especially in elderly patients, in
metastatic cancer and during corticosteroid medication. For that reason, identification of
neuropathy-related muscular weakness is challenging. In the present study, every third to
fourth patient reported motor symptoms, but they were no more than mild (only grade 1),
without any objective findings. This is in line with earlier reports (Park et al, 2011). Thus, the
prognostic significance of these findings is questionable.
Intraepithelial nerve fibers
The principal finding of the IENF (V) study was that IENF densities can be noticeably
reduced in cancer patients, even prior to starting adjuvant chemotherapy implying that
neurotoxic chemotherapeutic agents can not be solely blamed for neuropathy. Some
patients could develop paraneoplastic small fibre neuropathy, which may be subclinical at
first, but it may amplify the impact of neurotoxicity of chemotherapy (Lipton et al, 1991) were
first to demonstrate a subclinical small fibre dysfunction in cancer patients untreated with
chemotherapeutic agents. In line with our findings, they found that 50 % of cancer patients
had elevated thermal thresholds.
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Contrary to our preliminary hypothesis, neurotoxic chemotherapy does not always induce
loss of IENFs. Also the normalization of fibre count may happen during the chemotherapy.
Burakgazi et al (Burakgazi et al, 2011) reported a significant reduction in IENF density in
patients receiving oxaliplatin with similar different evolutional patterns as in some patients of
our study. However, we did not found any association between the IENF count and
neurological symptoms, which can be, at least partly, due to small number of patients and
many different patterns in evolution of IENF counts in the present study. The results of this
pilot study need to be confirmed in a larger patient population with longer follow-up and
combined IENF and QST.
Prevention of CIPN
The present study is the first prospective randomized controlled study of the efficacy of
amitriptyline, one of the most potent treatments of peripheral neuropathy with various
ethiologies, e.g., diabetic neuropathy, PHN and postsurgical neuropathic pain (Kalso et al,
1996; Saarto and Wiffen 2010) in prevention of CIPN. In line with the previous prevention
studies with other agents, the present study failed to demonstrate any effect of amitriptyline
in prevention of CIPN. However, we can´t rule out a small difference (below 30 %) between
the study groups because of the small size of this study. In our study, the daily dose of
amitriptyline was up to 100 mg, which is in line with the studies on painful neuropathy (Wolf
et al, 2008). Amitriptyline has been shown to prevent post-herpetic neuralgia even at a low
dose of 25 mg daily (Bowsher, 1997). However, the intensity of neuropathic symptoms in the
present study was rather low, which could have diluted the effect. Interestingly,
anticonvulsants, like gabapentin and carbamazepine have also failed to show any efficacy
over placebo in prevention of CIPN (Mitchell et al, 2006; von Delius et al, 2007). The results
of some other drugs tested in the prevention of chemotherapy-induced neuropathy such as
amifostine, diethyldithiocarbamate, glutathione, leukaemia inhibitory factor, N-acetylcysteine,
nimodipine, hexapeptide analogue Org 2766, and vitamin E have also been inconsistent
(Wolf et al, 2008). As yet, no neuroprotective drugs are recommended for routine use to
prevent CIPN in clinical practice.
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Treatment of CIPN
TCAs together with anticonvulsants are the first-line and most effective drugs for neuropathic
pain (Saarto and Wiffen 2010; Bril et al, 2011). The present stydy (II) was the first
prospective, randomized, controlled study of the efficacy of amitriptyline in treatment of CIPN
symptoms.
In our study amitriptyline did not, however, improve sensory neuropathic symptoms even
though there was a trend towards global improvement in favour of the amitriptyline group.
The study was premature interrupted because of the low recruitment rate with statical power
of finding the 30 % difference between the study groups. A relatively low dose (50mg/day) of
amitriptyline was chosen to avoid adverse events and increase compliance. However,
amitriptyline has been demonstrated to be effective in relieving postoperative neuropathic
pain in women with breast cancer already in doses of 25-50 mg/day (Kalso et al, 1996). In
line with the present study, another small study of nortriptylin in cisplatin-induced painful
neuropathy also failed to demonstrate any significant improvement in neuropathic
symptoms. Duloxetine has impaired oxaliplatin-induced neuropathy in an open-label study.
However, it has many adverse effects and interractions with other drugs like tamoxifen
(Yang et al, 2011).
Two clinical studies of gabapentin on chemotherapy-induced neuropathic symptoms have
also been published (Bosnjak et al, 2002; Rao et al, 2007). A small uncontrolled study
reported promising results with a 900 mg daily dose of gabapentin (Bosnjak et al, 2002), but
a placebo controlled prospective randomised study with 115 patients failed to alleviate pain
intensity or sensory neuropathic symptoms with 2700 mg of gabapentin (Wong et al, 2005).
So far, no treatment is available for clinical use in treatment of chemotherapy-induced
neuropathy.
Challenges in prevention and treatment of CIPN
CIPN is an important adverse effect as it may limit the dose of the anti-cancer treatment and
reduce the QoL of cancer patients and survivors. Neuroprotective therapies have been
sought for coadministration of chemoprotective or rescue therapies to reduce adverse
effects without reversing anti-tumor activity.  Various agents have been tried in clinical and
experimental models to prevent CIPN, but, so far, no treatment is available for clinical use in
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prevention of CIPN due to inefficiency or safety problems (Argyriou et al, 2011). One of the
most promising neuroprotective treatments have been Ca/Mg infusions. In a retrospective
study, Ca/Mg infusions before and after oxaliplatin treatment reduced the incidence of acute
neurologic symptoms, and the oxaliplatin therapy was less freguently discontinued due to
neurotoxicity among patients who were pretreated with Ca/Mg infusion (Gamelin et al, 2004).
However, in the prospective study there was alerting findings of a significantly lower tumor
response rate in the group receiving calcium/magnesium infusions and the study was closed
prematurely (Hochster et al, 2007).
The mechanism behind CIPN is not fully understood. Although TCAs and anticonvulsants
are effective treatments of painful diabetic neuropathy and PHN, their efficacy in CIPN has
not been proven yet. Interestingly, also in HIV related neuropathy TCAs (Kieburtz et al,
1998; Shlay et al, 1998) and gabapentin (Hahn et al, 2004) have failed to improve
neuropathic symptoms. Lamotrigine showed statistically significant pain relief in a small
randomised controlled trial of painful HIV neuropathy (Simpson et al 2000), but in a larger
randomised controlled trial the efficacy was shown only in those patients who had received
neurotoxic antiretroviral therapy (Simpson et al, 2003).
Neuropathies of different causes seem to respond differently to therapies that may reflect
differences in the mechanisms of neuropathies from various aetiologies. Another plausible
explanation could be the different symptom profile. The most prominent symptoms of
chemotherapy-induced neuropathy are paraesthesia, dysaesthesia and numbness, which
may be less responsive to pharmacotherapy than neuropathic pain dominating in other
neuropathies.
Despite the lack of significant improvement in neuropathic symptoms, amitriptyline
significanltly improved QoL of patients with advanced cancer. Amitriptyline was also well
tolerated. None of the patients quitted amitriptyline treatment because of side effects. Thus,
in selected patients with advanced disease, low dose amitriptyline could be still beneficial.
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SUMMARY AND CONCLUSIONS
Chemotherapy-induced neuropathy is a common adverse effect. Approximately two thirds of
the patients treated with neurotoxic chemotherapy reported neuropathic symptoms. In the
present study the intensity of neuropathic symptoms was relatively low. However, the
intensity and inconvenience of the neuropathic symptoms do not correlate with each other.
Neuropathic symptoms seem to be very troublesome despite of the low intensity.
There are many tools to assess neuropathic symptoms. In oncology the NCI-CTC scale is
used most widely. The oxaliplatin neurotoxicity scale has been used only in grading
neurotoxicity induced by oxaliplatin so far. We compared the above mentioned scales in
grading CIPN. Both scales were equally sensitive in detecting early CIPN in patients treated
with neurotoxic chemotherapy agents other than oxaliplatin. However, the oxaliplatin scale
was more sensitive in showing progression in the form of the duration of the symptoms. The
fact that the oxaliplatin scale more sensitively detected the progression of neurotoxicity could
be important, because early progression of neuropathic symptoms might reflect more severe
toxicity later in the chemotherapy course or neuropathic pain later in life. Hence, oxaliplatin
scale seems to be useful in grading CIPN not only in patients treated with oxaliplatin but also
those treated with other neurotoxic agents. It´s advantage is that it takes into account the
duration of symtomps.
Despite the fact that TCAs and anticonvulsants are the most effective drugs in treatment of
painful peripheral neuropathies, they have not been effective in the treatment or prevention
of CIPN. In the present studies amitriptyline failed to prevent or treat CIPN. Thus, there is no
effective treatment option for prevention or treatment of CIPN so far. However, despite the
lack of siginificant effect of amitriptyline in treatment of CIPN, in treatment of patients with
advanced cancer, amitriptyline may improve QoL.
IENF density can be markedly reduced in cancer patients, even prior to starting adjuvant
chemotherapy, which could partly influence the development of commonly encountered
abnormalities in sensation and neuropathic pain during chemotherapy.
In summary, CIPN is a common adverse effect of neurotoxic chemotherapy regimens.
Despite being often rather mild, it causes considerable discomfort to patients due to its often
chronic character. There is no standard global method for either assessment, prevention or
treatment of CIPN, other than limitiation of the total dose or changing the treatment schedule
of neurotoxic agents.
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1. Chemotherapy-induced neuropathy is a common adverse effect with low intensity.
However, the intensity and inconvenience of the neuropathic symptoms do not
correlate with each other. Neuropathic symptoms seem to be very troublesome
even though the intensity of the symptoms is generally mild.
2. The NCI-CTC sensory scale and the oxaliplatin scale are equally sensitive in
detecting early CIPN in patients treated with neurotoxic chemotherapeutic agents,
also other than oxaliplatin. However, the oxaliplatin scale is more sensitive in
showing progression in the form of the duration of the symptoms. Hence, it seems
to be useful in grading CIPN both in patients treated with oxaliplatin and in those
treated with other neurotoxic agents.
3. Amitriptyline does not seem to prevent chemotherapy neurotoxicity.
4. Amitriptyline improves QoL of cancer patients even though it does not significantly
improve symptoms of CIPN.
5. Density of IENF can be markedly reduced in cancer patients, even prior to starting
adjuvant chemotherapy, but the changes in the IENF density are not associated
with clinical symptoms of neuropathy.
79
ACKNOWLEDGEMENTS
This study was conducted at the Department of Oncology and Department of Obstetrics and
Gynaecological Oncology, Helsinki University Central Hospital, during the years 2002- 2006
and at the Department of Oncology, Tampere University Central Hospital, during the years
2007-2009. I am grateful to Professor Heikki Joensuu, MD, PhD,  for providing me with the
opportunities to undertake research work.
I owe my supervisor, Professor Tiina Saarto, MD, PhD, my deepest gratitude for introducing
me to the world of clinical research. I also thank her for her encouraging attitude in every
phase of the work and for her endless patience throughout all these years.
I am also grateful to my other supervisor, Docent Maija Haanpää, MD, PhD for her
enthusiasm, impressive knowledge in the field of neurology, and the ability to always provide
new ideas.
My gratitude also goes to Professor Eija Kalso, MD, PhD, whose expertise and advice have
been invaluable.
I am deeply grateful to Professor Pirkko Kellokumpu-Lehtinen, MD, PhD, for providing me
with the opportunities for research work and for her unique skill to always create a positive
atmosphere at work. All her help and advice is appreciated and valued.
I also thank Chief of clinic group Petri Bono,MD, PhD for providing the opportunity to
organize my work at the clinic in a way that allowed the completion of this work.
I thank the official reviewers of this thesis, Professors Johanna Mäenpää, MD, PhD and
Seppo Soinila MD, PhD, for their constructive comments and valuable aid in the final
preparation of the work.
I wish to express my gratitude to all the co-authors and other collaborators of the published
manuscripts: Mika Koskinen, MD, for good collaboration and guidance to skin biopsy
reseach and Docent Aki Hietaharju, MD, PhD  for providing valuable comments on the
manuscripts. Hannu Kautiainen´s MSc, enormous work and help with the statistics is greatly
acknowledged. I would also like to acknowledge the contribution of Docent Arto Leminen
MD, PhD, Ilkka Räisänen, MD and Mikko Loukovaara, MD, PhD at the Department of
Obstetrics and Gynaecological Oncology for all the extra work they took on with my study
patients.
I am grateful to all the colleagues at the Department of Oncology, Helsinki and Tampere
University Hospitals who helped me with this work.
My sincere gratitude goes to everyone in the Docrates-team for their positive
encouragement and warm support.
I greatly appreciate the help provided by Minna Sarelahti, MD, for her careful proofreading of
this thesis.
I am greatly indebted to Heini Koskinen, RN and Helena Juutinen RN, for all the practical
help, time spent with the patients and never-failing interest in this research during all these
80
years. I also thank Tuula Nuuttila, RN and Emmi Vettenranta, RN who have worked with the
V study in Tampere University Hospital.
I express my warmest thanks to Olli and Kirsti for their encouragement, patience and
support. Thank You Lila, Jarno and Salla for being the great joy of my life.
I thank all my friends for their long-lasting loyalty and endless support as well as enjoyable
and memorable moments, especially those in opera with Marika, hiking with Leila, Eija and
Arja and canoeing with Minna.
This work was supported by a grant from the Cancer Society of Finland, the Finnish Medical
Society Duodecim and Ida Montin Foundation, which I gratefully acknowledge.
Espoo, March 2012
Anna-Liisa Kautio
81
REFERENCES
Aapro M, Finek J. Oral vinorelbine in metastatic breast cancer: A review of current clinical
trial results. Cancer Treat Rev. 2011 Jul 8. [Epub ahead of print]
Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing
therapy-induced toxicity. Cancer Invest. 1990;8(2):147-59.
Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing
neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2011
Feb 16;(2):CD005228.
Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr
Oncol. 2011;18(1):18-25.
Almadrones L, McGuire DB, Walczak JR, Florio CM, Tian C. Psychometric evaluation of two
scales assessing functional status and peripheral neuropathy associated with chemotherapy
for ovarian cancer: a gynecologic oncology group study. Oncol Nurs Forum. 2004;31(3):615-
23.
Amara S. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Ann Pharmacother. 2008;42(10):1481-5.
Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and
mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth.
2011; 107(4):490-502.
Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral
neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol. 2011 Sep 9. [Epub ahead of print]
Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T,
Gerolymos MK, Gourzis P, Assimakopoulos K, Kalofonos HP. Efficacy of oxcarbazepine for
prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology.
2006;67(12):2253-5.
Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP.
Peripheral nerve damage associated with administration of taxanes in patients with cancer.
Crit Rev Oncol Hematol. 2008a;66(3):218-28.
Argyriou AA, Marmiroli P, Cavaletti G, Kalofonos HP. Epothilone-Induced Peripheral
Neuropathy: A Review of Current Knowledge. J Pain Symptom Manage. 2011;42(6):931-40.
Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on
xaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008b;34(4):368-77.
Astellas Pharma Europe Ltd: Summary of product characteristics: Qutenza 179 mg
cutaneous patch. 2011. European Medicines Agency, London, UK, (accessed 14 November
2011).
82
Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T; European
Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of
neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-23.
Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P, Jr., Rauck R, Tobias J: NGX-
4010, a  high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a
randomised, double-blind study. Lancet Neurol 2008;7:1106–12.
Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-
related side effects and their management. Eur J Oncol Nurs. 2009;13(1):49-59.
Bakitas MA. Background noise: the experience of chemotherapy-induced peripheral
neuropathy. Nurs Res. 2007;56:323-31.
Balducci L, Extermann M. Management of cancer in the older person: a practical approach.
Oncologist. 2000;5:224-37.
Behin A, Psimaras D, Hoang-Xuan K, Leger JM. Neuropathies in the context of
malignancies. Curr Opin Neurol. 2008;21:534-9.
Bennett GJ. Pathophysiology and animal models of cancer-related painful peripheral
neuropathy. Oncologist. 2010;15 Suppl 2:9-12.
Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, Gianni L.
Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced
neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 2005;41(12):1746-50.
Binder A, Stengel M, Maag R, Wasner G, Schoch R, Moosig F, Schommer B, Baron R. Pain
in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive
system. Eur J Cancer. 2007;43(18):2658-63.
Bosnjak S, Jelic S, Susnjar S, Luki V. Gabapentin for relief of neuropathic pain related to
anticancer treatment: a preliminary study. J Chemother. 2002;14(2):214-9.
Botez SA, Herrmann DN. Sensory neuropathies, from symptoms to treatment. Curr Opin
Neurol. 2010;23:502-8.
Bouhassira D, Attal N, Fermanian J, Al-Chaar M, Gautron M, Boureau F, Grisart J,
Masquelier E, Rostaing S, Collin E, Lanteri-Minet M. Development and validation of the
Neuropathic Pain Symptom Inventory. Pain 2004;108: 248–57.
Bowsher D. The effect of pre-emptive treatment of postherpetic neuralgia with amitriptyline:
a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage1997;13: 327-
31.
Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ,
Perkins B, Russell JW, Zochodne D; American Academy of Neurology; American
Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of
Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful
diabetic neuropathy: report of the American Academy of Neurology, the American
83
Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy
of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758-65.
Burakgazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M. Longitudinal
assessment of oxaliplatin-induced neuropathy. Neurology. 2011;77(10):980-6.
Campone M, Cortes-Funes H, Vorobiof D, Martin M, Slabber CF, Ciruelos E, Bourbouloux E,
Mendiola C, Delgado FM, Colin C, Aslanis V, Fumoleau P. Vinflunine: a new active drug for
second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic
study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J
Cancer. 2006;95(9):1161-6.
Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents:  occurrence
and management approach. Clin Breast Cancer. 2011;11(2):73-81.
Cavaletti G. Chemotherapy-induced peripheral neurotoxicity: how can we improve
knowledge? Lancet Oncol. 2009;10:539-40.
Cavaletti G, Alberti P, Frigeni B, Piatti M, Susani E. Chemotherapy-induced neuropathy. Curr
Treat Options Neurol. 2011;13(2):180-90.
Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol.
2010;6(12):657-66.
Chaudhry V, Chaudhry M, Crawford TO, Simmons-O'Brien E, Griffin JW. Toxic neuropathy
in patients with pre-existing neuropathy. Neurology. 2003 Jan;60(2):337-40.
Cleeland CR, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad
Med 1994;23:130-8.
Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T. Total
neuropathy score: validation and reliability study. Neurology. 1999;53(8):1660-4.
Cortes J, Montero AJ, Glück S. Eribulin mesylate, a novel microtubule inhibitor in the
treatment of breast cancer. Cancer Treat Rev. 2011 May 6. [Epub  ahead of print]
Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB,
Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL. Intravenous calcium and magnesium for
oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin
Oncol. 2011;29(4):421-7.
Cruccu G, Anand P, Attal N, Garcia-Larrea L, Haanpää M, Jorum E, Serra J, Jensen T.
EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004;11:153-162.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I,
Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate
cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet.
2010;376(9747):1147-54.
84
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes
H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F,
Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-
line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-47.
de Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral
neuropathy: a short review. CNS Drugs. 2007;21 Suppl 1:39-43;discussion 45-6.
Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R,
Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F. Efficacy of venlafaxine for the
prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a
randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200-5.
Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA,
Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD,
Turk DC, Wallace MS. Pharmacologic management of neuropathic pain:evidence-based
recommendations. Pain. 2007;132(3):237-51.
Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD,
Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz
S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath
P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L,
Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J. IMMPACT. Core outcome measures for
chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9–19.
England JD, Asbury AK. Peripheral neuropathy. Lancet. 2004;363(9427):2151-61.
England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, Cohen JA, Fisher
MA, Howard JF, Kinsella LJ, Latov N, Lewis RA, Low PA, Sumner AJ. Distal symmetrical
polyneuropathy: definition for clinical research. Muscle Nerve. 2005;31(1):113-23.
England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti
K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann DN, Howard JF Jr, Lauria
G, Miller RG, Polydefkis M, Sumner AJ; American Academy of Neurology. Practice
Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve
biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of
Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and
American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72(2):177-84.
Fornier MN. Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones
and their analogues. Clin Breast Cancer. 2007;7(10):757-63.
Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A. Adjuvant radiotherapy and/or
chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev. 2011
Jan 19;(1):CD006812.
Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to
neuropathic pain: the Neuropathic Pain Scale. Neurology 1997;48:332–8.
Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A, Gamelin E.
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a
85
retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and
leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10(12 Pt 1):4055-61.
Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de
Gramont A. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no
impact on its efficacy. J Clin Oncol. 2008;26(7):1188-9.
Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S,
Homesley HD, Braly P, Ritch PS, Weisberg SR, et al. Randomized placebo-controlled
multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-
induced toxicities. J Clin Oncol. 1995;13(2):490-6.
Garcia SF, Cella D, Clauser SB, Flynn KE, Lad T, Lai JS, Reeve BB, Smith AW, Stone AA,
Weinfurt K. Standardizing patient-reported outcomes assessment in cancer clinical trials: a
patient-reported outcomes measurement information system initiative. J Clin Oncol.
2007;25(32):5106-12.
Ghosh K, Ghosh K. Advances in haematological pharmacotherapy in 21st century. Indian J
Hematol Blood Transfus. 2010;26(2):30-40.
Gøransson LG, Mellgren SI, Lindal S, Omdal R. The effect of age and gender on epidermal
nerve fiber density. Neurology. 2004;62(5):774-7.
Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P.
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as
first-line therapy for metastatic breast cancer. JClin Oncol. 2009;27(22):3611-9. Epub 2009
May 26. Erratum in: J Clin Oncol. 2011;29(19):2739.
Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the
treatment of postherpetic neuralgia. Clin J Pain. 2000;16(3):188-92.
Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB,
Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL. Intravenous calcium and magnesium for
oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin
Oncol. 2011;29(4):421-7.
Haanpää M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, Cruccu G, Hansson P,
Haythornthwaite J, Iannetti G, Jensen T, Kauppila T, Nurmikko T, Rice A, Rowbotham M,
Serra J, Sommer C, Smith B, Treede R-F. NeuPSIG guidelines on neuropathic pain
assessment. Pain 2011;152:14-27.
Hahn K, Arendt G, Braun JS, von Giesen HJ, Husstedt IW, Maschke M, Straube ME,
Schielke E; German Neuro-AIDS Working Group. A placebo-controlled trial of gabapentin for
painful HIV-associated sensory neuropathies. J Neurol. 2004;251(10):1260-6.
Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen
GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter
LM. American Society of Clinical Oncology 2008 clinical practice guideline update: use of
chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27(1):127-45.
86
Hlubocky A, Wellik K, Ross MA, Smith BE, Hoffman-Snyder C, Demaerschalk BM,
Wingerchuk DM. Skin biopsy for diagnosis of small fiber neuropathy: a critically appraised
topic. Neurologist. 2010;16(1):61-3.
http://bme240.eng.uci.edu/students/10s/mklopfer/anatomy.html   (viite Fig. 2)
Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce
oxaliplatin-related neurotoxicity. J Clin Oncol. 2007;25(25):4028-9.
http://clinicaltrials.gov
Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx
subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology
group study. Int J Gynecol Cancer. 2007;17(2):387-93.
Hughes R. Peripheral nerve diseases: the bare essentials. Pract Neurol. 2008;8(6):396-405.
Huskisson EC. Measurement of pain. Lancet 1974;2:1127–31.
Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, Treede RD. A new
definition of neuropathic pain. Pain. 2011;152(10):2204-5.
Joint Task Force of the EFNS and the PNS. European Federation of Neurological
Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of
small fiber neuropathy. Report of a joint task force of the EuropeanFederation of
Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst.
2010;15(2):79-92.
Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J
Haematol. 2009;145(1):3-14.
Kalso E, Tasmuth T, Neuvonen P. Amitriptyline relieves neuropathic pain following treatment
of breast cancer. Pain 1996;64:293-302.
Kanat O, Evrensel T, Baran I, Coskun H, Zarifoglu M, Turan OF, Kurt E, Demiray M, Gonullu
G, Manavoglu O. Protective effect of amifostine against toxicity of paclitaxel and carboplatin
in non-small cell lung cancer: a single center randomized study. Med Oncol. 2003;20(3):237-
45.
Kedar A, Cohen ME, Freeman AI. Peripheral neuropathy as a complication of cis-
dichlorodiammineplatinum (II) treatment: a case report. Cancer Treat Rep.1978;62:819-21.
Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention.
Lancet. 2006;367(9522):1618-25.
Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D,
Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and
cisplatin-induced toxicities: results of a randomized control trial in patients with advanced
ovarian cancer. J Clin Oncol. 1996;14(7):2101-12.
87
Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD, Ellis RJ, Marra CM, McKendall R,
Singer E, Dal Pan GJ, Clifford DB, Tucker T, Cohen B. A randomized trial of amitriptyline
and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol
Team. Neurology. 1998;51(6):1682-8.
Kiernan MC. The pain with platinum: oxaliplatin and neuropathy. Eur J Cancer.
2007;43(18):2631-3.
Koike H, Tanaka F, Sobue G. Paraneoplastic neuropathy: wide-ranging clinicopathological
manifestations. Curr Opin Neurol. 2011;24(5):504-10.
Koskinen M, Hietaharju A, Kyläniemi M, Peltola J, Rantala I, Udd B, Haapasalo H. A
quantitative method for the assessment of intraepidermal nerve fibers in small-fiber
neuropathy. . J Neurol. 2005;252(7):789-94.
Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA,
Berg AR, Stella PJ, Loprinzi CL. The use of vitamin E for the prevention of chemotherapy-
induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care
Cancer. 2011;19(11):1769-77.
Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rørth M, Krarup C. Neuronal
involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies.
Brain. 2007;130(Pt 4):1076-88.
Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler
JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D,
Smith RE, O'Connell MJ, Costantino JP, Wolmark N. Neurotoxicity from oxaliplatin combined
with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II
and III colon cancer: NSABP C-07. J Clin Oncol. 2007;25(16):2205-11.
Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin
Oncol. 2006;24(10):1633-42.
Lehmann HC, Chen W, Borzan J, Mankowski JL, Höke A. Mitochondrial dysfunction in distal
axons contributes to human immunodeficiency virus sensory neuropathy. Ann Neurol.
2011;69(1):100-10.
Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde E, Quasthoff S,
Grosskreutz J, Adelsberger H. Prevention of oxaliplatin-induced peripheral sensory
neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal
Cancer. 2002;2(1):54-8.
Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger F,
Lecouturier S, Descorps-Declère A, et al. A chronopharmacologic phase II clinical trial with
5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable
pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer.
1992;69(4):893-900.
88
Lhomme C., D. Berton-Rigaud, F. Joly, J. Baurain, F. Rolland, A. Stenzl, T. Schmelter, M.
Campone;   Results from a randomized phase II study to evaluate the safety and efficacy of
acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy (REASON).
2011 ASCO Annual Meeting  Abstract No: 9116.
Lipton RB, Galer BS, Dutcher JP, et al. Large and small fibre type sensory dysfunction in
patients with cancer. J Neurol Neurosurg Psychiatry 1991; 54: 706-9.
Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A, Maestroni G. Treatment of
cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care
Cancer. 1997a;5(2):126-9.
Lissoni P, Paolorossi F, Ardizzoia A, Barni S, Chilelli M, Mancuso M, Tancini G, Conti A,
Maestroni GJ. A randomized study of chemotherapy with cisplatin plus etoposide versus
chemoendocrine therapy with cisplatin, etoposide and the pineal  hormone melatonin as a
first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J
Pineal Res. 1997b;23(1):15-9.
Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione
L, Di Vagno G, Ferrau' F, Scambia G; Multicenter Italian Trials in Ovarian Cancer
invesitgators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-
line chemotherapy in ovarian cancer patients. Ann Oncol. 2003;14(7):1086-93.
Luckett T, King M, Butow P, Friedlander M, Paris T. Assessing health-related quality of life in
gynecologic oncology: a systematic review of questionnaires and their ability to detect
clinically important differences and change. Int J Gynecol Cancer. 2010;20(4):664-84.
McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol
Cancer Ther. 2009;8(1):10-6.
Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, Georgiou C,
Polyzos NP. Overall survival benefit for weekly vs. three-weekly taxanes regimens in
advanced breast cancer: A meta-analysis. Cancer Treat Rev. 2010;36(1):69-74.
Max MB. Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol.1994;35:50-3.
Melli G, Taiana M, Camozzi F, Triolo D, Podini P, Quattrini A, Taroni F, Lauria G. Alpha-
lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy
neuropathy. Exp Neurol. 2008;214(2):276-84.
Melzack R . The McGill Pain Questionnaire: major properties and scoring methods. Pain
1975;1:275–99.
Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191–197.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment.
Cancer. 1981;47(1):207-14.
89
Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Thomson
JA and Clarke S: Addition of gabapentin to a modified FOLFOX regimen does not reduce
oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer. 2006;6:146-51.
Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral
neuropathy and new treatments for multiple myeloma: background and practical
recommendations. Haematologica. 2010;95(2):311-9.
Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and
fibromyalgia in adults. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007938.
Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G,
Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S,
van de Velde H, Deraedt W, Harousseau JL. Subcutaneous versus intravenous
administration of bortezomib in patients with relapsed multiple myeloma: a randomised,
phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-40.
Nahleh Z, Pruemer J, Lafollette J, Sweany S. Melatonin, a promising role in taxane-related
neuropathy. Clin Med Insights Oncol. 2010;4:35-41.
Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL. Vincristine-induced
allodynia in the rat. Pain. 2001;93(1):69-76.
Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and
emerging therapies. Support Care Cancer. 2004;12(9):619-25.
Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-
resistant prostate cancer. Future Oncol. 2011;7(4):497-506.
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD,
Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH,
Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA,Pachucki CT,
Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE,Marques AR, Keay SK,
Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M,Keitel WA, Crawford GE, Yeh
SS, Lobo Z, Toney JF, Greenberg RN, Keller PM,Harbecke R, Hayward AR, Irwin MR,
Kyriakides TC, Chan CY, Chan IS, Wang WW,Annunziato PW, Silber JL; Shingles
Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in
older adults. N Engl J Med. 2005;352(22):2271-84.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP.
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol.
1982;5(6):649-55.
Pace A, Giannarelli D, Galiè E, Savarese A, Carpano S, Della Giulia M, Pozzi A, Silvani A,
Gaviani P, Scaioli V, Jandolo B, Bove L, Cognetti F. Vitamin E neuroprotection for cisplatin
neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74(9):762-6.
Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, Biroccio A, Leonetti C,
Jandolo B, Cognetti F, Bove L. Neuroprotective effect of vitamin E supplementation in
patients treated with cisplatin chemotherapy. J Clin Oncol. 2003;21(5):927-31.
90
Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapy-induced peripheral
neuropathy: prevention and treatment. Clin Pharmacol Ther. 2011;90(3):377-87.
Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the management of
advanced prostate cancer. Clin Interv Aging. 2010;5:395-402.
Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin-
induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Brain. 2009;132(Pt 10):2712-23.
Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Long-term
neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist.
2011;16(5):708-16.
Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and
why? Crit Rev Oncol Hematol. 2006;59(2):159-68.
Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human
multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase
inhibitors. Clin Cancer Res. 2004;10(11):3839-52.
Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on
mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8(8):2086-95.
Planting AS, Catimel G, de Mulder PH, de Graeff A, Höppener F, Verweij J, Oster W,
Vermorken JB. Randomized study of a short course of weekly cisplatin with or without
amifostine in advanced head and neck cancer. EORTC Head and Neck  Cooperative Group.
Ann Oncol. 1999;10(6):693-700.
Plasmati R, Pastorelli F, Cavo M, Petracci E, Zamagni E, Tosi P, Cangini D, Tacchetti P,
Salvi F, Bartolomei I, Michelucci R, Tassinari CA. Neuropathy in multiple myeloma treated
with thalidomide: a prospective study. Neurology. 2007;69(6):573-81.
Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan
K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R;  EORTC Quality of
Life Group. The development of an EORTC quality of life questionnaire to assess
chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer.
2005;41(8):1135-9.
Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol.
2002;249(1):9-17.
Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, Gross HM, Renno SI,
Nashawaty M and Loprinzi CL: Efficacy of lamotrigine in the management of chemotherapy-
induced peripheral neuropathy. Cancer 2008;112:2802-8.
Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny
P, Kutteh LA, Wong GY; North Central Cancer Treatment Group. Efficacy of gabapentin in
91
the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized,
double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110(9):2110-8.
Richardson P, Jagannath S, Colson K. Optimizing the efficacy and safety of bortezomib in
relapsed multiple myeloma. Clin Adv Hematol Oncol. 2006;4(5):1.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol
Neurosurg Psychiatry. 2010 Dec;81(12):1372-3. Saif MW, Syrigos K, Kaley K, Isufi I. Role of
pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res.
2010;30(7):2927-33.
Sartor O, Halstead M, Katz L. Improving outcomes with recent advances in chemotherapy
for castrate-resistant prostate cancer. Clin Genitourin Cancer. 2010;8(1):23-8.
Schierle C, Winograd JM. Radiation-induced brachial plexopathy: review. Complication
without a cure. J Reconstr Microsurg. 2004;20(2):149-52.
Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H,
Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH. Feasibility and validity of the
Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized
trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009;17(12):1483-
91.
Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, Wentworth D, Hillman S, Brizz B,
Cohn DL. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a
randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.
JAMA. 1998;280(18):1590-5.
Simpson DM, Brown S, Tobias J: Controlled trial of high-concentration capsaicin patch for
treatment of painful HIV neuropathy. Neurology 2008;70:2305–13.
Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, Baird BJ, Barrett P, Hammer
AE; Lamotrigine HIV Neuropathy Study Team. Lamotrigine for HIV-associated painful
sensory neuropathies: a placebo-controlled trial. Neurology. 2003;60(9):1508-14.
Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K. A placebo-
controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology.
2000;54(11):2115-9.
Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common
chemotherapeutic agents. Cancer Chemother Pharmacol. 2009;63(5):761-7.
Sommer C, Lauria G. Skin biopsy in the management of peripheral neuropathy. Lancet
Neurol. 2007;6(7):632-42.
Stengel M, Baron R. Oxaliplatin-induced painful neuropathy--flicker of hope or hopeless
pain? Pain. 2009;144(3):225-6.
92
Stevens PE, Dibble SL, Miaskowski C. Prevalence, characteristics, and impact of
postmastectomy pain syndrome: an investigation of women's experiences.
Pain.1995;61(1):61-8.
Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, Gooch CL.
Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy:
a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol). 2005;17(4):271-6.
Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis,
incidence, and management. Clin Adv Hematol Oncol. 2008;6(6):455-67.
Takemoto S, Ushijima K, Honda K, Wada H, Terada A, Imaishi H, Kamura T. Precise
evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale:
a quantitative and comparative analysis of neuropathy occurring with paclitaxel-carboplatin
and docetaxel-carboplatin therapy. Int J Clin Oncol.  2011 Aug 19. [Epub ahead of print]
Tankisi H, Pugdahl K, Fuglsang-Frederiksen A, Johnsen B, de Carvalho M, Fawcett PR,
Labarre-Vila A, Liguori R, Nix WA, Schofield IS; Esteem Project. Pathophysiology inferred
from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested
guidelines. Clin Neurophysiol. 2005;116(7):1571-80.
Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR,
Fuller JH; EURODIAB Prospective Complications Study Group. Vascular risk factors and
diabetic neuropathy. N Engl J Med. 2005;352(4):341-50.
Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral
neuropathy. Clin J Oncol Nurs. 2010;14(3):E22-8.
Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D,
Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS,
Balmaceda C. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin
Cancer Res. 2001;7(5):1192-7.
Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay
A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of
docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian
carcinoma. J Natl Cancer Inst. 2004;96(22):1682-91.
Velasco R, Bruna J. Chemotherapy-induced peripheral neuropathy: an unresolved issue
Neurologia. 2010;25(2):116-31.
von Delius S, Eckel F, Wagenpfeil S , Mayr M, Stock K, Kullmann F, Obermeier F, Erdmann
J, Schmelz R, Quasthoff S, Adelsberger H, Bredenkamp R, Schmid RM and Lersch C:
Carbamazepine for prevention of oxaliplatin related neurotoxicity in patients with advanced
colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest
New Drugs 2007;25:173-80.
von Schlippe M, Fowler CJ, Harland SJ. Cisplatin neurotoxicity in the treatment of metastatic
germ cell tumour: time course and prognosis. Br J Cancer. 2001;85(6):823-6.
93
Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chiou TJ, Liu JH, Yen CC, Chen
PM. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal
cancer patients. Oncologist. 2007;12(3):312-9.
Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul  J, Hay
A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of
docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian
carcinoma. J Natl Cancer Inst. 2004;96(22):1682-91.
Wiffen PJ, Derry S, Moore RA. Lamotrigine for acute and chronic pain. Cochrane Database
Syst Rev. 2011;(2):CD006044.
Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral
neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44(11):1507-15.
www.dartmouth.edu/~humananatomy/figures/chapter_3/3-2.HTM
Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Lin CC, Yen
CC, Tzeng CH, Wang WS, Chiang HL, Teng CJ, Teng HW. Duloxetine improves oxaliplatin-
induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support
Care Cancer. 2011 Aug 4. [Epub ahead of print]
Zheng H, Xiao WH, Bennett GJ. Functional deficits in peripheral nerve mitochondria in rats
with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol.
2011;232(2):154-61.
Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, Samigullin R, Tritschler H,
Munzel U, Maus J, Schütte K, Dyck PJ. Efficacy and safety of antioxidant treatment with -
lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care.
2011;34(9):2054-60.
